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HISTORICAL 
Some of the biological activities of the posterior pitui­
tary hormone, vasopressin, have been known for many years. In 
1859 Oliver and Schafer (109) found that extracts of the whole 
pituitary gland were capable of increasing the blood pressure 
of a dog when injected intravenously. Three years later 
Howell (66) demonstrated that the substance responsible for 
this pressor action was obtainable only from the posterior 
lobe of the pituitary. 
While studying the pressor action of posterior lobe ex­
tracts, Dale (23) in 1909 noted that these crude extracts 
also had a uterine contracting or. oxytocic effect. The next 
year Ott and Scott (110) recognized a milk-ejecting action on 
the mammary gland by these extracts. 
In 1912 Frank (45) postulated a relationship between the 
neurohypophysis and diabetes insipidus, a disease character­
ized by a large increase in urinary secretion. He believed 
that the disease was due to an excessive outpouring of a 
diuretic hormone from the pituitary, von den Velden (163) and 
Farm! (41) tried injections of posterior lobe extracts on 
cases of diabetes insipidus and were surprised to learn that 
these preparations had an antidiuretic effect and could be 
used successfully to treat the disease. 
All of these biological activities were attributed to a 
single substance until 1928 when Kamm et al. (73) worked out 
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a separation scheme which gave two active fractions. These 
crude fractions were given the commercial names Pitressin and 
Pitocin. Tne vasopressin fraction exhibited most of the 
pressor and antidiuretic activities, and the oxytocin the 
uterine contracting and galactogogic effects. 
Kamm and his coworkers achieved their separation by a 
hot dilute acetic acid extraction of acetone-dried posterior 
pituitary tissue and a series of solvent and salt precipita­
tions. Little was known acout the chemical structure of the 
active principles at that time except that they were basic 
and procably amines. 
After further purification of the Kamm extract from beef 
pituitsries by electrophoresis (70) and countercurrent dis-
tricution (159), hydrolysis of the highly active vasopressin 
fraction revealed that it contained cystine, tyrosine, phenyl­
alanine, glutamic acid, aspartic acid, proline, arginine and 
glycine in approximately equimolar ratios. Three moles of 
ammonia were also present. 
Performic acid oxidation indicated that the disulfide 
linkage of cystine formed a cyclic structure (ill). Amino 
acid sequence studies, utilizing the dinitrofluorobenzene 
method of Sanger (132), the stepwise degradation scheme of 
Edman (40) and trypsin cleavage, enabled Acher and Chauvet 
(l) and du Vigneaud et al. (38) in 1953 to propose a struc­
ture for arginine vasopressin: 
3 
I D —D I 
H-Cys-Tyr-Phe-G-lu( KHg) -Asp( KHg) -Cys-Pro-Arg-Gly( NHg) 
The final proof of this structure came when du Vigneaud. end 
his coworkers (36) synthesized arginine-vasopressin in 1954 
and demonstrated that it possessed the same biological and 
chemical properties as the hormone isolated from beef pitui-
taries. 
An interesting species difference was discovered when a 
purified vasopressin fraction from hog pituitaries was 
hydrolyzed. .Lysine was found to have replaced arginine (112). 
du Vi^neaud1s Lroup also synthesized the porcine hormone (38). 
The syntheses of arginine and lysine vasopressins have 
made availacle hormones which are known to be free of pitui­
tary contaminants having other biological activities. With 
synthetic vasopressin the biological activities intrinsic to 
this hormone can be investigated. 
Biological Activities of Vasopressin 
Pressor activity 
The increase in blood pressure produced by injection of 
vasopressin is due mainly to the constriction of the arteri­
oles or proximal parts of the capillaries (60). Immediately 
after the injection the heart beat becomes slightly slower, 
but the force of the beats of both the auricle and ventricle 
are augmented (109). Vasopressin seems to affect the 
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musculature of the heart and blood vessels directly because 
severing the spinal cord does not abolish the pressor action. 
For many years vasopressin has been considered unimpor­
tant physiologically in the control of cardiovascular func­
tion, because it vas necessary to inject large pharmacologic 
doses to demonstrate a blood pressure increase. In the dog 
200 mU. of vasopressin had to be injected to produce a satis­
factory pressor response although the antidiuretic action of 
as little as 0.25 mU. could be detected (160). Recently, by 
measuring coth blood flow and pressure in the femoral artery, 
Potter and Sutfin (116) have shown that vasopressin injected 
intre-arterially in doses of 0.1 to 5 cV. induced vasocon­
striction without significant elevation of blood pressure. 
Kitchin (80) also observed a vasoconstriction after in­
fusion of Pitressin when he studied blood flow in the human 
hand and forearm. An- increase in capillary resistance .was 
noted by Kramar et al. (81) in man after an intramuscular 
injection of 30 mU. of vasopressin although no antidiuretic 
activity could be demonstrated. At a higher dose of 1 U. 
coth effects were observed. Vasopressin appears to be vaso­
active as well as antidiuretic at low levels. 
Pressor activity is usually assayed by directly cannu-
lating the carotid artery-and then measuring the rise in 
blood pressure following the intravenous injection of a 
sample. The assay animal frequently chosen is the anesthe­
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tized rat. The method of Dekanski (29) utilizing the di-
benamine-bioeked rat will be discussed in detail later. 
Antidiuretic activity 
The antidiuretic effect of this hormone is illustrated by 
the decrease in urine volume which occurs after Injection of 
vasopressin into a hydrated animal. Vasopressin increases the 
rate of water reabsorption in the kidney so that the osmotic 
pressure of the urine is raised above that of the plasma. 
The role of the antidiuretic hormone in urinary electro- • 
lyte excretion has been very difficult to assess. Thorn (157) 
has reviewed the conflicting literature and discussed possible 
sources of variation in results. 
The location of antidiuretic action in the nephron of 
the kidney has been studied by two different approaches. 
Direct information about the composition of the fluid in 
various parts of the nephron has been obtained by micropunc-
ture of the tubules. Wlrz (164) has perfected this tech­
nique. The Indirect method is based on renal clearance 
studies, which measure the rates at which the kidney excretes 
various substances relative to their concentration in the 
plasma-
From the results of clearance experiments Smith (152) 
has proposed a widely accepted theory that there must be 
three separate sites and three different mechanisms of water 
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reabsorption in the mammalian kidney. In the proximal tubule 
there is an active reabsorption of the solutes and, to main­
tain an isoosmotic state, a passive reabsorption of the water. 
Eighty to 90 per cent of the filtered water is reabsorbed 
here. In the distal tubule there is a further active re-
absorption of sodium, and if antidiuretic hormone is present, 
water also is reabsorbed. The maximum dose of vasopressin 
will promote water reabsorption until the distal tubule fluid 
is isotonic. Dilution of the urine will occur with lower 
doses. At the third site, water must be actively abstracted 
to concentrate the isotonic tubule fluid above the osmotic 
pressure of plasma. Smith believes that this process occurs 
in the collecting ducts• 
Wirz has suggested another theory for concentration of 
the urine. He has proposed that there is a hair-pin counter-
current system in the loops of Henle. This countercurrent 
concentrating mechanism is initiated by the antidiuretic 
hormone when it opens the pores in the descending limb and 
allows water to pass out of the tubule. 
Although the exact location of antidiuretic action is 
not clear, increasing membrane permeability appears to be 
the primary function of the hormone. In 1960 Schwartz and his 
coworkers in an interesting series of papers (43, 118, 146) 
suggested a scheme for a mechanism of action of vasopressin 
on membrane permeability at the molecular level. Their in-
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vestimations of the interactions of tritiated vasopressin 
with rat kidney or toad bladder indicate that a covaient bond 
is formed between the hormone and the membrane proteins. A 
disulfide-thiol exchange reaction results in a hormone-
receptor disulfide bond. This group proposed that following 
this initial reaction a series of disulfide-sulfh'ydryl reac­
tions may alter the tertiary structure of the memerrne pro­
teins to such an extent that water and certain solutes can 
now easily pass through. 
. Evidence for the.disulfide bond was substantiated by the 
release of 46-58 per cent of the bound vasopressin after 
treatment with cysteine, me reapto ethylamine or thioglycolaté. 
Complete inhibition of vasopressin action occurred at high 
concentrations of the sulfhydryl reagents, K-ethyl-maleimide 
or méthylmercuric bromide. This is the first identification 
of a physiologically significant chemical bond formed between 
a hormone and a. target organ. 
These workers also suggested that the very low activities 
of acetylated and iodir.ated vasopressins may be due to specif­
ic stereochemical and electrostatic requirements between the 
hormone and its receptor for the formation of the disulfide 
bond. 
The substitution of lysine in porcine vasopressin for 
arginine has shown an interesting species difference in anti­
diuretic potency. In dogs van Dyke et al. (162) found that 
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1 U- of lysine vasopressin had only one-sixth the antidiuretic 
activity of 1 U. of arginine vasopressin. When lysine vaso­
pressin was injected into rrts, Sawyer (133) noted that the 
antidiuresis was as intense as with arginine vasopressin but 
the duration of the antidiuresis was less. In the pig, the 
porcine hormone lysine vasopressin had the same or perhaps 
even greater antidiuretic activity than arginine vasopressin 
( 104 ) . 
Thorn (157) has written a critical evaluation of the 
procedures which have been used to measure antidiuretic 
activity. He concluded that intravenous injection of the 
sample into an anesthetized hydra ted rat and measurement of 
the osmolality of the urine as the index of antidiuretic 
response gave the most reliable results. 
Recently de Wied (30) devised an automatic feedback 
system that maintained the hydration of the rat at a rate 
identical to the rate of urine excretion. With this pro­
cedure there was little variation in baseline urine output • 
and urine flow could be used as the index of antidiuretic 
activity, vaji Dyke et aJL. ( 160) preferred heavily hydrated, 
unanesthetized dogs. 
Oxytocic activity 
The structure of oxytocin is identical to that of 
arginine-vasopressin except that isoleucine and leucine have 
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replaced phenylalanine and arginine respectively. With this 
close chemical relationship it is not surprising that vaso­
pressin has some oxytocic activity. 
Fitzpatrick (42) has listen two effects of oxytocin on 
the uterus. In the non-pregnant female at the time of mating 
the uterine contractions propel the seminal fluid toward the 
rallopisn tubes. At parturition the contractions help to 
expel the foetus. In the mammary gland oxytocin exerts a 
milk ejecting effect by causing a contraction of the myo­
epithelia of the alveoli (22). 
There are many oxytocin assay systems, such as the iso­
lated rat uterus, chicken clood pressure, milk ejection pres­
sure in the racbit mammary gland, the cat uterus in situ and 
othtrs (10). The relative oxytocic activity of vasopressin 
seems to depend on the assay procedure used. The following 
tacle compares the values obtained with highly purified 
arginine-vasopressir. and oxytocin. 
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Corticotropin releasing activity 
'The existence of a hypothalamic neurohumoral mediator 
that regulates adrenocorticotropin (ACTH) release under con­
ditions of stress v;as postulated by de G-root and Harris (27, 
28) and independently by Hume ( 58). The experimental evidence 
from wnich de G-root and Harris formulated this- theory was 
that electrical stimulation of the hypothalamus of a rabbit 
gave a reduction in the number of circulating lymphocytes 
similar in magnitude and time relation to that following an 
emotional stress stimulus or an injection of ACTH (27, 28). 
Hume (63) obtained similar results using unanestnetized dogs 
and eosinopenia as an index of release of ACTH from the 
anterior pituitary. These investigators and others (46, 97, 
115) demonstrated that lesions in the hypothalamus inhibited 
stress-induced release of ACTH. 
The posterior pituitary hormones, vasopressin and oxy­
tocin, are elaborated by neurosecretory cells in the hypo­
thalamus (7, 145). By suitable staining techniques (122) 
the neurosecretory material containing the hormones can be 
traced from its origin in the supraoptic and paraventricular 
nuclei of the hypothalamus dovm the axons of the hypothalamo-
hypophysial tracts to the posterior pituitary. Here the hor­
mones are stored until released. Recent evidence Indicates 
that there are direct vascular connections from the posterior 
to the anterior lobe of the pituitary (24). 
Lauber (84) demonstrated that there is a correlation 
after bilateral adrenalectomy in the rat between the release 
of the antidiuretic hormone (ADH) and the loss of stainsble 
secretory material. She did this b;y comparing bio assays of 
plasma ADH levels with censitometric estimations of the 
neurosecretory material. ' 
kirsky ejc al. (103) also have presented evidence that 
vasopressin is formed in the hypothalamus rather than in the 
posterior pituitary. They found that hypophysectornized, 
a.tirenalectomized rats responded .to noxious stimuli by a marked 
increase in plasma antidiuretic activity. Because both ADH 
release from the hypothalamus and ACTH release from the 
anterior pituitary occurred in response to adrenalectomy or 
noxious stimuli, these workers proposed that the antidiuretic 
hormone might serve as the hypothalamic neurohormone which 
activated the anterior pituitary. 
Hypothalamic lesions which destroyed the supraoptico-
hypophyseal tract clocked ACTH release, but kcCann and Brobeck 
(94) were able to induce ACTH discharge with large doses 'of 
Pitressin. The minimal effective dose of Pitressin was 
approximately 600 mU. in these rats, which were tested three 
or more weeks after lesioning. ACTH activity was measured by 
adrenal ascorbic acid depletion. Later kcCann and Fruit (95) 
discovered that rats which had been lesioned only 48 hours 
prior to the assay were more sensitive to Pitressin. The 
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minimum effective dose for the acute hypothalamic-lesioned 
rets was 100 mU. Linear log dose response was demonstrated 
from 100 to 1000, mU- of pressor activity. Synthetic lysine 
vasopressin evoked an almost identical response in these ani­
mals. It is interesting to note that Pitressin, which is 
usually a mixture of beef and pork.vasopressins, had only 83 
per cent of the potency of synthetic lysine vasopressin at 
the•same pressor dosage. 
• kcDonald and his coworkers (99) tried intravenous in­
fusions of .Pitressin and highly purified arginine and lysine 
vasopressins in man. Adreriocorticotropin release was measured 
by the increase in concentration of free ^-hydroxy-corti­
costeroids in the plasma. Two units of highly purified lysine 
vasopressin gave an increase more than twice that observed 
for two units of arginine vasopressin. The response to 
Pitressin was only slightly lower than that given by lysine 
vasopressin, and the authors concluded that a__1 the ACTH--
releasing activity of Pitressin could be accounted for by its 
pressor content. To investigate the possibility that Pitres­
sin and the vasopressins isolated from natural sources might 
contain contaminants having ACTH-releasing ability these 
workers (100) also compared Pitressin and synthetic lysine 
vasopressin. They ruled out the existence of an active con­
taminant after finding no significant difference between the 
17-hydroxy-corticosteroid levels given by 2 U. of synthetic 
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lysine vasopressin and EU. of Pitressin. 
Steroid-clocked rets have been used as assay animals. 
Sixelik and de ".vied ( 151) administered prednisolone. Twenty-
four hours later the sterold-inhibited rats showed no adrenal 
ascorbic acid depletion with adrenaline or serotonin. Only 
Pitressin was effective. 
Casentini et al. (19) blocked nonspecific stimuli in the 
rat with 9-alpha-fluoro-hydr^cortisone. Intravenous injec­
tions of 300 mU. of Pitressin and lysine vasopressin gave 
significant adrenal ascorbic aciu depletion. With intra-
carotia injections of Pitressin much smaller doses, 5 to £4 
mUwere effective. Pitressin did not exert a direct effect 
on the adrenals nor contain ACTH, because 300 'mU. produced no 
fall in adrenal ascorbic acid in hypophysectomized rats. 
Another interesting experiment performed by this group 
was with hypophysectomized rats bearing functional pituitary 
grafts in the anterior chambers of their eyes. Acetylcholine, 
histamine, serotonin, Pitocin and synthetic oxytocin did not 
release ACTH when injected directly into the graft. Pitressin 
did at the low level of 10 mU. 
In 1955 an in vitro assay system was devised by Saffran 
and Schally (130). Corticotropin-releasing factors were 
detected by their ability to release ACTH from rat anterior 
pituitaries incubated in vitro. In this assay hypothalamic 
tissue alone was inactive but the combination of hypothalamic 
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tissue with artereno 1 or epinephrine increased ACTH release 
threefold. Posterior pituitary tissue plus arterenol was even 
more active and increased ACTH release six to eight times. 
G-uillemin and Hearn (5 2 )  also independently developed 
an in vitro assay. Pitressin released ACTH in their system 
when cultured with anterior pituitaries for four days, but 
purified vasopressin did not. These results led the investi­
gators to suggest that the ACTH-releasing activity of Pitres­
sin might ce due to an active contaminant of this commercial 
meter!al rather than the vasopressin. 
Saffran and his group" (131) also reached the same con­
clusion after tney had .separated a cortico tropin-re1er sing 
factor (CRF)'from Pitressin by paper chromatography in two 
systems, cutanol:acetic acid:water (4:1:5) and water-saturated 
phei.ol. 
G-uillemin and his coworkers (53) prepared a more active 
AC'TH-releasing fraction (Fraction D) by paper chromatography 
in acetone:dietnylene glycol'.0.5>- aqueous ur-a (6:1:3).' In 
this system Fraction D ran close to the front with a mean Hf 
value of 0.9. The pressor-containing fraction (Fraction B) 
wes found at a mean Rf of 0.4. Only these two fractions 
showed ACTH-releasing ability with Fraction D almost twice 
as active as the pressor fraction. 
Fraction D obtained from posterior pituitary tissue was 
active in the Saffran and Schally in vitro assay at 100yug. 
It had a low pressor activity (4 to 50 mU•/mg.) and some 
melanocyte stimulating hormone (MSH) activity. Hypothalamic 
Fraction D had 30 to 100 times greater CRF activity, no vaso­
pressin effect and more XSH activity. 
Electrophoresis of- the posterior pituitary Fraction D in 
acetic acid concentrated the activity in a D-delta fraction 
which stimulated ACTH release at 0.5 to 2.5 /Ag. in the in ' 
vitro assay. The D-delta fraction upon hydrolysis showed 17 
amino acids and therefore was believed to be'a mixture of pep­
tides . 
Schally et. al. ( 144) obtained a highly active CRF by 
using a series of four chromatographic systems, butanol: 
acetic acid:water- (4:1:5), water-saturated m-cresol, acetone: 
water (3:2), and propahol:water (4:1). This CRF fraction was 
active in releasing ACTH at doses as low as 1 nyxg. Hydrolysis 
of this fraction consistently showed the amino acids of lysine 
vasopressin plus major amounts of serine and histidine and 
smaller variable proportions of alanine and arginine. 
Schally (139, 143) also tested various vasopressin 
preparations in the in vitro assay. Lysine vasopressin 
purified to 200 U./mg. showed a 40 per cent increase in ACTH 
release at a level of 0.5yUg., but this result was not 
statistically significant. Synthetic lysine'vasopressin with 
an activity of 300 U./mg. was active at a dose of 0.067yug. 
cut not active at 0. 5yxg • or 0.002 ug • However, only one 
assay at the high level was reported. 
Commercial Pitressin was active in the slightly modified 
in vitro system of Swingle et al. (156)• An ACTH-releasing 
fraction was separated from the pressor fraction by counter-
current distribution or by destruction of the pressor activity 
b. hydrolysis. Later in an addendum to their reprints this 
group admitted that their in vitro assay gave non-specific and 
irreproducible results (55). 
In 1959 Nichols and Guillemin (108) published the results' 
of a study of the effects of endogenous end exogenous vaso­
pressin on ACTH release in unanestnetized dogs. They found 
no correlation between antidiuresis and ACTH release measured 
by increase in the 17-hydroxy-corticostercids• When lysine 
vasopressin was injected into the carotid artery the dose 
required to stimulate ACTH. secretion was 300-0 to 7000 times 
the amount of vasopressin needed to produce maximal anti­
diuresis. These workers felt that vasopressin could not be 
the mediator of both responses unless there was e large 
sensitivity difference between the two reactions. 
McDonald and his group (98) found a variation in the 
responses of normal human subjects to stresses of fluid 
deprivation, hypertonic saline, nicotine, hand immersion in 
ice water and insulin-induced glycemia. Endogenous ADH re­
lease without an increase in ACTH, or a rise in ACTH without 
a detectable release of vasopressin, occurred in these sub­
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jects even under the seme stress. These authors concluded 
that there was no correlation in the release of the two 
hormones. 
de ivied (32) noted that ACTH release in response to 
neurogenic stress such as strange environment, sound, and 
pain, required vasopressin. Compared with controls, rats 
which had been neurohypophysectomized had low levels of 
plasma free corticosterone after neurogenic stress but treat­
ment with Pitressin tannate restored pituitary response. 
However, when the neurohypophysectomized rats were exposed • 
to systemic stress such as hemorrhage, histamine injection, 
or nicotine injection, the ACTH-response was similar to that 
of the sham-operated controls. This is an interesting differ­
ence in response to two types of stress. 
In 1958 G-uillemin et al. ( 54) introduced sn in vivo CRF 
assay utilizing rats blocked with nembutal plus morphine: 
The release of ACTH was determined by measuring the concen­
tration of free corticosterone in the plasma by the fluoro-
metric method of Silber et al. (149) as modified by G-uillemin 
et al. (49). In these pharmacologically blocked rats a linear 
log dose relationship was observed between ACTH release and 
Fraction D in the range of 10 to 1000yx.g . Almost identical 
results were obtained when Fraction D was injected into rats 
with lesions of the median eminence of the hypothalamus. 
When highly purified lysine vasopressin (287 U./mg.) was 
tested in the in vivo assay, G-uillemin et al. (51) concluded 
that there was a threshold for ACTH release at 80-100 mU. of 
pressor activity. At 80 mU. of pressor activity there was a 
large ACTH release (150/2 increase in plasma corticoids over 
controls) and from this point AÇTH release increased linearly 
with the log dose of vasopressin. Below 30 mU• no statis­
tically significant discharge occurred. To eliminate this 
ACT'H-relessing activity of high pressor dosages, it was sug­
gested that all samples should be diluted to 30 mU. of pressor 
activity before being assayed for CRF. 
work on purification of CRF continued. In 1259 for 
larger scale preparation Schally and G-uillemin ( 141) concen­
trated CRF by chromatography on cnrboxymethylcellulose (CMC). 
Column fractions were assayed at 30 pressor milliunits in 
nembutal-morphine-blocked rats. The pressor and CRF activ­
ities had very similar mobilities- on the CMC column, but the 
maximum CRF activity was found in the early tubes of the 
vasopressin peak. 
The chromatographic behavior on CMC and IRC-50 cation 
exchange resin of highly purified'arginine and lysine vaso­
pressins, ot-MSH and ACTH were studied by Schally and 
Guillemin (14%), in order that their locations would be known 
when crude pituitary extracts were chromatographed. CRF 
activity appeared to follow oxytocin and precede lysine vaso­
pressin, o<-MSH, arginine vasopressin and ACTH on CMC columns, 
19 
cut lysine vasopressin, c<-M5H and CRF moved very close to­
gether. On IRC-50 oxytocin and lysine vasopressin moved 
ahead of the CRF, but c<-KSH, arginine vasopressin and ACTH 
came off the column near the peak of ACTH-releasing activity. 
• Porter and Rumsfeld (113, 114, 129) obtained blood from 
the hypo thaiamico-hypophyseal portal vessels of dogs in order 
to test for the presence of the neurohumoral agent in the blood 
draining the hypothalamus. After low-temperature alcohol 
fractionation of the blood plasma proteins by the method of 
Cohn et al. (21) the ACTH-releasing activity was found only 
in fraction IIIQ • The injection of a fraction IIIQ prepared 
from carotid artery blood did not cause reduction in the 
adrenal ascorbic acid of the hydrocortisone-inhibited rat. 
The CRF activity of portal vessel plasma fraction IIIQ was 
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labile to trypsin and pepsin. It also was destroyed by re-
fluxing 1 hour in 0.1 K sodium hydroxide cut not by 2 hours 
of re fluxing in 0.1 N hydrochloric acid. 'Dialysis data indi­
cated that the active factor was associated with a large 
carrier protein. 
An ACTH-releasing fraction also was prepared by Rumsfeld 
and Porter (128) from an acetone extract of beef hypothalami. 
After chromatography on Dowex 50x2 resin with volatile formate 
buffers, the active materiel was fractionated by counter-
current distribution (CCD) in sec-butano,l and 0.05 per cent 
acetic acid. Paper chromatography in buta.no 1:acetic acid: 
water (4:1:5) of the fast and slow-moving CCD components gave 
single spots with Rf1 s of 0.64 and 0.41 respectively. Argi­
nine and lysine vasopressins are usually found at 0.15 and 
0.11 in this system. 
Additional evidence for a CRF distinct from vasopressin, 
and ACTH was found by Royce and Bayers (126). Acetic acid 
extracts of calf hypothalamus gave adrenal ascorbic acid de­
pletion in median eminence lesioned rats even after .absorp­
tion of 85-80 per cent of the pressor activity or. oxycellu-
lose• This CRF was pepsin-labile, whereas the pressor activ­
ity and the activity, of added ACTH were unaffected by pepsin. 
kcCann and Haberland (96) corroborated these results by 
obtaining acid extracts of beef or rat stalk-median eminence 
area in which vasopressin accounted for only 10 to 20 per cent 
of the ACTH-releasing activity of the fraction. However, in 
contrast to the oxycellulose purification of the CRF by Royce 
and Bayers, kcCann and Haberland found that the oxycel.lulose 
adsorbed almost all of the ACTH-releasing material. • In acetic 
acid extracts of posterior pituitaries vasopressin alone 
accounted for all the corticotropin-releasing activity. 
Further purification of the hypothalamic ACTH-releasing 
material was achieved in 1960 by Royce and Bayers (127) by 
chromatography on CMC columns. Discontinuous gradient elution 
with 0.05, 0.1, 0.2 and 0.4 M ammonium acetate buffers gave 
two active fractions. These CRF fractions emerged with the 
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0.01 lu sud 0.1 k eluents, -whereas the 0.2 k buffer coi.tained 
most of the pressor activity, and ACTH was found in the 0.4 
k eluate. These results suggested thst there might ce two 
chemically distinct CRFs. 
In karch of 1960 Guillemin et al. (57) reported that in 
three different CCD systems CRF activity corresponded to the 
%t-kSH peak. de Garilhe and his coworkers (26) also obtained 
a CRF fraction that appeared to ce closely related to c<-kSH. 
All the amino acids of -kSH were present in this fraction 
plus threonine and leucine. The CRF material and c^-kSH did 
not appear to ce identical because of the two additional amino 
acias, the low kSH activity of the CRF fraction and the pre­
viously observed low ACTH-releasir;g activity of highly purified 
o(-k5H and synthetic formyl . o<-kSH. 
In June of I960 Guillemin and his group (56) proposed 
that there was evidence for two chemically distinct CRFs in 
porcine posterior pituitary. One was closely related to 
c<-MS:i and was named o(-CRF, while the other, (5-CRF, was 
associated with vasopressin. They had separated <x.-CRF from 
ot-MSH by a CkC column and paper chromatography in butanol: 
acetic acidiwater (4:1:5) and m-cresol:water (95:5). The 
oc-CRF contained all the amino acids of o<_-k5H plus thre­
onine, leucine and alanine. It was active at relatively high 
dosages, 2-3_>cg. in the in vivo CRF assay and 0.5 jug in vitro • 
Its KSH activity was 0.1 to 0.3 x 107 U./mg. and inherent ACTH 
activity 0.1 U./mg • The pressor activity of ©C -CRF was very 
low, O.l-O.jc TJ./mg. 
The (3-CRF was detected on the descending edge of the 
vasopressin peak after CCD in n-butanol:0.3 K o-toluene-
sulphonic acid (140). In this system the vasopressin peak 
was well separated from the ck.-1-iSE end <=<-CRF area. A par­
tial separation of ^-CRF from vasopressin was obtained by 
the same series of paper chromatographic systems originally 
developed by Schally et a_l. (144). (3-CRF was much more 
active at 0.05 yug. in vitro and 0.1 yxg. in vivo than ol-CRF. 
Guillemin end his coworkers (140) proposed that ol-CRF may 
be only a precursor in the biosynthesis of ACTH and that 
^-CRF is the true chemical mediator of ACTH release. 
The discovery of <k.-C?.F has helped to explain the ACTH-
releasing activity of unst of the fractions which were care­
fully characterized as different from vasopressin. Lazzari 
(86) has re-evaluated the published data on corticotropin-
releasing factors and was able to classify almost all as 
either -CRF or (3-CRF. The question still remains, however, 
whether (3 -CRF is a separate entity or a manifestation of the 
inherent ACTH-releesing ability of vasopressin. This problem 
will only be resolved by either isolation of a chemically 
distinct (5-CRF or proof that vasopressin itself is the most 
active corticotropin-releasing factor. 
Sideman and Sobel (148) have concluded that lysine veso-
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pressin is the CRF of the guinea pig. By electrophoresis in 
acetate buffer a fraction was isolated from Pitressin that 
was active in releasing corticoids and contained only the 
eight amino acids of vasopressin.. 
Kwaan and Bartelstone (82) injected a very small dose, 
2 mU., of arginine vasopressin directly into the third ven­
tricle of the brain of a dog and found a significant rise in 
the adrenal corticoids. Intraventricular Injections of 2 mU. 
of oxytocin or intravenous injections of 20 mU. of arginine 
vasopressin did not increase the 17-hydroxy-corticosteroid 
levels. These results illustrate that smaller doses of vaso­
pressin may be effective if they can reach the pituitary 
directly via the portal vessels. 
A direct vasopressin stimulation of the isolated adrenal 
gland was shown by Hilton ejt al. (63). With direct arterial 
perfusion minimal activity was detected with doses as lov; as 
7 mU- of arginine vasopressin. Royce and Bayers (125) also 
noted an extrapituitary action of vasopressin after intra­
venous injection of large doses (2.5-5.0 U.) into hypophysec-
tomized or decapitated rats. Other investigators (48, 96, 
148) were unable to demonstrate a direct effect on the adren­
als by intravenous injections. 
One of the greatest problems in assessing corticotropin 
activity has been the development of a sensitive and reliable 
assay. According to McCann (93, p. 673): 
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. . . the ideal assay animal to test for possible 
neurohumoral activators of ACTH release would be 
one in which the ubiquitous pituitsry-adrenal 
response to stress wss completely blocked while 
leaving unimpaired the sensitivity of the pitui­
tary and adrenal to the neurohumor and ACTH, 
respectively. 
Bayers et al. (137) in their 1958 review stated that none of 
the current CRF bio assays completely met all of these require­
ments. 
Saffran et _al. (loi) developed the 11 vitro pituitary 
assay to avoid some of the complexities of in vivo assays. 
However, three groups (8, 44, 1^4) suggested that the assay 
was not specific but that the increase in ACTH was due to 
inhibition of the degradation of ACTH or to leakage from the 
pituitary cells rather than secretion of the hormone. 
G-uillemin and Schally (55) re-evaluated the technique and con­
cluded there was no destruction of ACTH in the system under 
the conditions used and, therefore, there could be no inhibi­
tion. In their hands the in vitro assay was specific for 
corticotropin-releasing factors, because there was a correla­
tion in the data obtained with the in vitro and in vivo assays. 
The severe limitation of this method is that it does not show 
a linear log dose response with increasing doses of CRF. 
Consequently, it remains a qualitative rather than a quantita­
tive test. 
Rats with hypothalamic lesions have been used as assay 
ajiimals (54, 94, 126), but there has been so much disagreement 
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over the sensitivity of these animals that it is difficult to 
interpret the assay data. Royce and Sayers (126) observed . 
that median eminence lesloned rats gave the same response to 
AC Tri as did ^4-hour hypophysec tomizea rats. i-lcCann and Haber-
land (96) stated that rats with lesions were three times less 
sensitive to ACTH than hypophysectomized rats. Dear end 
Guillemin (25) found lowered adrenal response to ACTH but a 
compensatory increase in pituitary sensitivity. 
The presence of diabetes insipidus was not considered 
as an adequate guide to animals with "effective" hypothalamic 
lesions by Guillemin and his group (51). Eighteen to 19 hours 
after lesioning they stressed the rats with ether. Only those 
an i... a Is with low cla sma corticosteroid levels were selected. • 
Ko correlation.was observed between the inhibition of stress-
induced ACTH release and diabetes insipidus. 
, de Wied (31) used a slightly different method to judge 
the effectiveness of hypothalamic lesions in rats. Corticoid 
production by the left adrenal in vitro after ether anesthesia 
was the index of the effectiveness of the lesion. Immediately 
after the removal of the left adrenal, the essay sample was 
injected. Fifteen minutes later the right.adrenal was re­
moved. Steroidogenesis by the right adrenal in vitro 
measured the CRF activity of the sample. The log dose re­
sponse curve obtained was linear between 5 and 180 mU. of 
Pitressin. Purified lysine vasopressin gave similar results 
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in this assay • 
Hydrocortisone and morphine ere used as clocking agents 
in CRF assay animals witn the assumption that these agents 
act on the hypothalamus to inhibit the release of the neuro­
hormone in response to nonspecific stimuli. The exact site 
or mode of action of these ?gents is not known. 
iuorphine does not interfere with the response of the 
adrenal to ACTH ( 18) but in steroid-blocked rats the adrenal 
sensitivity is less than that of hypophysectomized rats (19). 
Morphine plus nemcutal anesthesia is also relatively more 
effective tns.n corticosteroids in the inhibition of reaction 
to intense stimuli such as laparotomy and unilateral adrena­
lectomy (107). Perhaps the greatest advantage of the 
nembutal-morphine-blocked r?t is that there is no destruc­
tion of the vascular and nervous tissue as there is in elec­
trolytic lesioning. 
Leeman ejt al- (87) and Kunson (106) have suggested that. 
CRF assays must be performed in both moruhine-nembutal-blocked 
animals and in animals anesthetized with nembutal alone. They 
•-
have proposed that the true CRF will give the same response 
in both, cut a. non-specific stress would be inhibited in the 
morphine-blocked animal. A crude hypothalamic extract pre­
pared by this group (88) gave essentially the same effect in 
both assays while the response to 80 mU. of Pitressin was 
reduced in the morphine-blocked animals. However, the crude 
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extract contained some ACTH and vasopressin and perhaps KSH 
and csC-C'.HF since no measurements of MS H activity were made 
on the extract. Further purification of- this crude hypo­
thalamic material must be carried out to reveal the nature 
of its CRF activity. 
For many years ACTH release has been assessed by the 
Sayers and Sayers (138) adrenal ascorbic acid depletion 
method. In 1958 Slusher (150) noted that lesions in the 
posterior and midcentral partions of the hypothalamus specif­
ically inhibited corticosterone release without altering the, 
ascorbic'acid c.epl-etion response to stress. Lesions, in the 
basal tuberal area inhibited 'adrenal ascorbic acid depletion 
"but had no effect on steroid release-
When Guillemin et_ al. (51) measured both adrenal ascorbic 
acid depletion and plasma corticosteroid levels in the same 
animals, variations in corticoid levels were found with no 
change in the adrenal ascorbic acid concentration. The 
fluorometric determination of corticosterone in rats appears 
to be a more direct and sensitive measurement of adrenal 
response to ACTH release. 
Other activities of vasopressin 
In 1955 Ingle and Li (69) observed another interesting 
property of vasopressin. This was its ability to enhance ' 
work performance in adrenalectomiz'ed, hypophysectomized rats. 
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Sreter and Friedman (154) suggest this.effect is due to a 
direct action by vasopressin on cationic exchanges across 
muscle membranes. 
Vasopressin and oxytocin stimulate the oxidation of glu­
cose in mammary gland slices (47). Vasopressin has one-sixth 
the activity of oxytocin, a ratio similar to the ratio of 
their milk-ejection activities, A glycogenolytic effect of 
vasopressin in the canine liver has also been observed (11). 
Biological Activities after Inactivatlon of Vasopressin 
Inactivation studies of a hormone are of great interest 
because they may offer some clues as to its mode of action. 
These studies are also practical because of Isolation and 
storage problems. 
Adamsons e_t al. (5) studied the spontaneous decomposition 
at room temperature of synthetic and natural neurohypophysial 
hormones in aqueous buffers over a pH range of 3.0-8.5. Par--
tially purified synthetic lysine vasopressin (38 U./mg.) 
showed maximal stability at pH 3 and 5 with 87 to 90 per cent 
of its activity still remaining at the end of 28 days. 
Arginine vasopressin also was most stable at the same acidic 
pHs. A highly purified arginine vasopressin (400 U./mg.) 
decomposed faster than a crude sample (175 U./mg.,). There 
was a. parallel loss of both antidiuretic and pressor activ­
ities during the destruction of the vasopressins. 
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The enzymes pepsin pnd pancreatic cnrcoxypeptidase do not 
affect vasopressin (156). Trypsin cleaves between the car-
bo xyl group of arginine or lysine and the adjoining amino 
group of glycine. Trypsin has been used to destroy the pres­
sor activity of a crude sample without harming the oxytocin 
(105). 
Hooper (65) has prepared a soluble vasopressinase, prob­
ably a peptidase, from human placenta. Slices of mammalian 
kidney have also been shown to inactivate vasopressin (153). 
t 
T;iis system may contain several, enzynic activities directed 
toward either the disulfide or amide bonds. 
Chemical reduction of the disulfide bond of vasopressin 
lea^s to loss of pressor and antidiuretic activity. Ames et_ 
al. (6) incubated Pitressin in a 0.01 K solution of thio-
giycolate at pH 7.5. After &. 5 hours at room temperature 
only c per cent remained of the original antidiuretic activ­
ity of 100 mU./ml. Schelly (139) used the same conditions 
to study CRF activity and found that al± pressor activity of 
a crude pituitary extract was destroyed but the results on 
CRF were inconclusive. When the thioglycolate concentration 
was increased to 0.05 k and the time of the reaction to. 24 
hours, both activities were abolished. 
Oxidative cleavage of the disulfide bond with performic 
acid;also destroyed the pressor (111) and CRF activities 
(139)• 
Sideman end Sobel (146) used inactivetion studies to 
support their contention that lysine vasopressin is the cor-
ticotropin-releasing factor in the guinea pig. After mild 
acid and alkaline hydro lysis, iodine tion and indication with 
placental extract both the CRF and pressor activities of 
Pitressin were reduced tc the same extent. 
In a footnote to his paper on the direct adrenal action 
of vasopressin Hilton _et al. (63) stated that the ACTH-like 
activity of vasopressin v." a s lost after £ hours at room 
temperature in a'saline solution although there was no loss 
of pressor activity under these conditions. 
Biological Activities of Vasopressin Analogues 
The relation of chemical structure to hormonal activity 
also has been studied by means of analogues. The two vaso­
pressins, arginine vasopressin and lysine vasopressin, have 
been found in the neurohypophyses of many mammals. Arginine 
vasopressin, originally isolated from beef, has also been 
i d e n t i f i e d  a s  t h e  p r e s s o r  h o r m o n e  o f  m a n  ( 9 1 ) ,  h o r s e  ( 2 ) ,  
sheep (3), cat, dog, ret, rebbit, camel, monkey (161), opossum 
and spiny anteater (135). Lysine vasopressin, the porcine 
hormone, has been found in only one other animal, the hippo­
potamus (61). 
Two other naturally occurring analogues of vasopressin 
are known. Oxytocin, the other posterior pituitary hormone 
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of mammals, could ce called isoleucine -leucines-vasopressin. 
In order to designate various analogues of lysine vasopressin 
the following numbering system has been used. 
I ' S—S • r 
Cys-Tyr-Phe- G-lu ( K Hp ) - A s p ( I\TH .-> ) - C y s- P r o - Ly s- Gly ( NH.-, ) 
1 2 3 4  5  6  7  B  9  
Recently vasotocin, Ileu°-Arg^-vasopressin has been identified 
from the pituitaries of chickens (20, 105), fish (62, 117, 
136), frogs (4), alligators :( 135), turtles and lamphreys 
(134). 
This new hormone, containing the ring of oxytocin and 
the side-chain of arginine vasopressin, was synthesized in 
IS58 by Katsoyannis and du Vigneaud (78) before it was dis­
covered as a natural product. The presence of arginine in 
the side chain increases the pressor activity above that of. 
oxytocin, while the oxytocin ring structure gives higher 
avian depressor response than that of the vasopressins. 
The chemical synthesis of arginine vasopressin and lysine 
vasopressin opened the way for the synthesis of many analogues 
of the natural hormones. These analogues afford an excellent 
opportunity to study the relationship between structure and 
biological activities. 
Table 2 lists the ciological activities of lysine vaso-
% 
pressin and closely related synthetic polypeptides. Ileu -
vasopressin is the lysine analogue of vasotocin. Arginine 
vasotocin and lysine vasotocin have very similar biological 
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U ./rng. • 
Rat uterine 
contracting 
u -A-g* References 
Lys-vasop. 280 ' . 30 .4 (34) 
Q 




125 150 75 (78) 
3 lieu -vasop. 
(Lys-vasotocin) 
130 190 (17, 79) 
Le u —vasop. 
(Oxypressin) 
3 45 20 (10, 16, 76) 
c 
His -vasop. 1.5 4.6 1.5 (77) 
2 
Phe -vasop-, • 55 0.5 <0.1 (15, 101) 
activities with lysine vasotocin showing slightly higher 
Q 
vrlues. Leu -vasopressin ir. contradistinction to vasotocin 
contains the ring portion of vasopressin linked to the tri-
peptide amide side chain of oxytocin. It is commonly called 
oxypressin. Substitution of leucine for the basic amino acids 
lysine or arginine decreased the pressor activity greatly. In 
8 
His -vasopressin a weakly basic emino acid was substituted 
for the strongly basic acids. The pressor activity of this 
polypeptide was very low. One of the requirements for high 
pressor activity appears to be a strongly basic amino acid 
in the side chain. 
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Another functional group in the lysine vasopressin mole­
cule is the hydroxy! group of tyrosine. The replacement of 
£ the phehol group by a phenyl to (jive Phe -vasopressin dimin­
ished the pressor activity but did not abolish it. The 
hydroxyl group is thus not essential. The replacement of 
phenylalanine in the third position by tyrosine, however, gave 
% 
very low pressor fctivity. Tyr' -vasopressin had 1.5 U./mg. 
2 3 • 
of pressor activity and Phe -Tyr -vasopressin had only 0.14 
U./mg. (15). 
du Vigrieaud and his group (39) have obtained further 
evidence that basicity may be very important for high pressor 
function. When the free amino group on the cystine residue 
was eliminated, the des ami no-1y s i ne vasopressin had only half 
the activity of the natural hormone. ^3-mercaptopropionic 
acid was used in the place of cysteine to prepare this ana­
logue . 
The addition of a methyl group to the nitrogen of the 
C-terminal peptide bond caused a marked loss of bio logical 
activity. This sarcosine9-lysine vasopressin had only 0.45 
U./mg. of pressor activity and no activity in the avian 
depressor and rat uterine contracting assays (102). The sub­
stitution of a methyl for a hydrogen on the imino group of 
the terminal peptide bond of the side chain may interfere 
with hydrogen bonding. 
The oxytocin analogues with non-basic leucine in the 
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side chain generally have very low pressor activity. The 
synthetic compounds have usually been compered in only three 
assays, the ret pressor assay and the two recommended for 
oxytocic- activity, avian depressor and rat uterine contract­
ing. Serde _et al. (10) heve suggested that all analogues 
should be tested in a battery of assays. The varying ratios 
of activities obtained with oxytocin analogues in five dif­
ferent .assays can be seen in Table 3. The substitution of 
valine or leucine for the third amino acid of oxytocin de­
creased the avian depressor and the rat uterine contracting 
activities much more than the milk ejection potency, whereas 
fr lieu -oxytocin showed much higher activity in the avian 
depressor assay than in any other test. A variety of bio­
logical assays are needed to characterize structural ana­
logues and also may be helpful in developing synthetic com­
pounds with highly desirable biological properties. 
Desamino-oxytocin ( 39) is an example of a. synthetic poly­
peptide with selective biological action. It had a higher 
avian depressor activity (578 U./mg.) than oxytocin but only 
one-third of its low pressor activity.. This analogue again 
illustrates that amino groups are not necessary for oxytocic 
activity. A desamino-desoxy-oxytocin in which phenylalanine 
had replaced tyrosine was relatively low in avian depressor 
activity (140 U./mg.). The presence of the phenolic group in 
ocytocin enhances its activity. The synthesis of (0-methyl-






an t i— 
diuretic 
U./mg. 








ej ect ion, 
roboit 
U./mg. References 
Oxytocin 5.0 5.0 450 450 450 (72) 
Ileu8-oxytocin 6.0 1.1 498 289 328 . (72) 
Val^-oxytocin 9.0 0.8 280 200 310 (72) 
3 Val -oxytocin 0.2 0.8 57 59 207 (10, 16, 72) 
% 
Leu -oxytocin ~5.0 5 .0 42 45 101 (10, 1G, 72) 
2 Phe -oxytocin — 1.0 ~ 1.3 63 31 141 (9, 14, 71) 
5 
Glu -oxytocin 0.0 0-0 < 1 <0.1 - 1 (10, 16) 
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Tyr) -oxytocin (65) and (K-methyl-Tyr) -oxytocin (67) resulted 
in compounds with less then 1 per cent oxytocic activity. 
du Vigneaud and his group (.55) have prepared glycyl-
oxytocin. This compound with glycine attached to the amino 
group of the cystine gave such unusual assay responses that 
no estimates of its potencies could ce made. The responses 
were very slow and prolonged as compared with the natural 
hormones. 
Ressler (119) discovered that the cyclic disulfide ring 
alone of oxytocin has low but significant rat uterine con­
tracting (3.3 U./mg.) and milk ejecting (1.1 U./mg.) activ­
ities . Changes in the size of the ring produce inactive com­
pounds. If tyrosine is eliminated from the ring,• the result­
ing heptapeptide amide disulfide is inactive. The enlarge­
ment of the ring by an additional tyrosine (59) results in a 
nonapeptide with negligible oxytocic activity. Beyerman and 
Bontekoe (12, 15) have prepared a tyrosine homologue of vaso­
pressin but did not report biological activities in their 
papers. 
The disulfide ring was expanded by one end two methylene 
units in isoasparsgine-oxytocin (92) and isoglutamine-oxytocin 
(120). Both of these analogues were inactive. Isoglutamine-
oxy tocin even inhibited the pressor activity of arginine 
vasopressin (121). 
Guttman and Bois sonnas (58). have prepared ten analogues 
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Table 4. Analogues of oxytocin and vasopressin 
Ser2 oxytocin Ser2-Ileu3--vasopressin 
Ser2--His3--oxytocin Ser2-His3- vasopressin 
His2--Phe3--oxytocin His^-Ser3- vasopressin 
Try3--oxytocin His2- vasopressin 
Ser3- vasopressin 
. Try - vasopressin 
of oxytocin and lysine vasopressin containing serine, histi-
dine or tryptophan in the second or third position. The 
oxytocic and vasopressic activities of all these analogues 
were lower than 1/1000 to 1/10000 of the corresponding 
activities of the parent hormones. 
Although many synthetic peptides related to ot -MSH have 
been tested and found to have corticotropln-releasing activ­
ity (26, 74, 75, 90), only a few analogues of vasopressin 
have been tried in CRF assays. Rinne et al. (123) found that 
oxytocin did not deplete ascorbic acid in the cortisone-
8 8 blocked rat. Neither Arg -oxytocin nor Leu -vasopressin pro­
duced any significant Increase in adrenal corticosteroid out- • 
put when injected directly into the third ventricle of the 
dog by Kwaan and Bartels tone (82) at levels of 5 >uug. 
MATERIALS AND METHODS 
Materials 
Princeton hog posterior pituitary powder 
Princeton Laboratories Inc. of Princeton, Kew Jersey 
(courtesy of Dr. William Kleinoerg) generously donated sev­
eral kilograms of hog posterior pituitary lobe powder. This 
powder had been prepared by acetone desiccation, homogeniza-
tion and lyophilizstion of the posterior pituitaries and had 
an oxytocin and pressor activity of approximately 1500 U./g» 
This powder was the starting material for most of the isola­
tion work. 
Continuous electrophoresis starting material 
The Princeton posterior pituitary powder was extracted 
according to the procedure developed by Kamm et el. (73). 
This extract, usually designated as Kamm product, had 4-5 
U./mg. of pressor activity. 
A large scale countercurrent distribution of Kamm 
product was carried out in n-butanol:acetic acid:water 
(4:1:5). After 14 transfers most of the weight and pressor 
activity remained in the first four tubes. Material from 
the leading edge, of the pressor peak (Tubes 2 and 3) was sub­
mitted to continuous electrophoresis. The Kamm extractions 
and the CCD were performed by Eugene Lazzarl end his assist­
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ant; details ere given in his Ph. D. thesis (86). 
Synthetic lysine vasopressin 
du Vigneaud lysine vasopressin Synthetic lysine vaso­
pressin was kindly provided by Dr. V. du Vigne?ud, Department 
of Biochemistryj Cornell University kedical College, ::ew York, 
N• Y• The sample (Jk V 68/16) was reported to contain 260 
International Units per. mg. In our laboratory two assays of 
this sample gave %58 U./mg. (Suz^ .fiducial limits 2c8-291) and 
c6? U./mg. (95," fiducial limits £56-279) . The mean of these 
two assays, 262 U./mg., was ta^en as the pressor activity of 
the sample• 
Sandoz vasopressin Synthetic lysine vasopressin 
(Batch Kc• 067 01) also was generously donated by Sandoz 
Pharmaceuticals Co., Hanover, K. J. (courtesy of Dr. H. 
Schwarz). This material was received in solution. Each 
sealed vial held 1 cc. of saline containing 10,000 mU. of 
pressor activity. 
Drugs 
Nembutal Powder was provided by Abbott Laboratories, 
North Chicago, 111. (courtesy of Dr.'J. D. Taylor). The 
heparin-sodium (Nutritional Biochemicals Corp., Cleveland, 
Ohio) was obtained in a powdered form having 100 U./mg. activ­
ity . Crystalline urethan (ethyl carbarn?te-Fisher Scientific 
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Company, Feirlevm,' K. J.) and USp-Powder morphine sulfate 
(kerck end Co., Inc., Rahway, !.. J.) were used. Fresh solu­
tions of all drugs were prepared before each bioessay. 
Animals 
Rats kale albino rats were obtained from the Holtzmen 
Company, maison, Wisconsin, rhe rats were shipped by Air 
Express and then kept in-the laboratory at least a wee& before 
tney were us~d 1'or cioasseys. 
Frogs J umbo size frogs (Rene pipiens) with light 
s Kin s were•purchased from S. G. Steii.hilber and Co., Oshkosh, ' 
Wisconsin, for the kSH assays. 
kethods 
Continuous flow electrophoresis 
A Spinco i'iode_ CP - Continuous Flow Paper Electrophoresis 
Cell was used with a Spinco Con-stet constant current supply• 
Prior to eech run the system was equilibrated with the elec­
trolyte, 0.5 i; acetic acid, for four to six hours. The flow 
rates of tne electrolyte to the side wicks end onto the hang­
ing curtain were adjusted until a trace of dye moved straight 
down the paper curtain. 
A I/o solution of the sample in the electrolyte we s pre­
pared . The sample was continuously fed et a rate of 0.9 ml. 
per hour onto a tac of the hanging curtain near the anode. 
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During the run the current was maintained at 30 mi Hi amps 
which provided 530-540 volts• The system was cooled by run­
ning, cold tap water through the cooling plate behind the hang­
ing curtain and by recirculating the electrolyte from a six 
liter bottle immersed in an ice bath. Every 24 hours the 
electrolyte was changed. 
• The electrophoresis fractions were numbered 1 to 32 from 
the cathode to the anode• All fractions were lyophilized. 
Bioassays 
Pressor assay The pressor activities of the vrrious 
samples were determined-by the method of Dekanski (29) with 
slight modifications. Rats' weighing 200 to 300 g. were in­
jected subcutaneously with urethan ( 190 mg./lOO g. B . V». ). 
After approximately two hours when the r°t was completely 
anesthetized, the trachea was cannulated with a short glass 
tuce, ax id one carotid artery was dissected ready for c annula­
tion . The femoral vein next to the inguinal ligament was 
cannulated with a needle, because the vein collapses easily 
with manipulation. Heparin (200 U./100 g. B. ¥.) was injected 
into the rat by way of the femoral vein. All the samples were 
administered in 0.2 ml. of physiological saline and washed 
into the femoral vein by an equal amount of saline. 
A polyethylene cannula inserted into the carotid artery 
led to a Statham pressure transducer (Model P23Db) which in 
turn-was connected to a Sanborn amplifier and recorder (Model 
141). The blood pressure of the rat was blocked by intra­
venous injections of die en amine (200-300 ymg./100 g. B. W.) to 
a case level of about 50 mm. Hg. Unknown samples were com­
pared witn two levels (4 mU. and 8 mU. ) of U3P Posterior, 
Pituitary Reference Standard. 
Cortlcotropin-releaslii# factor assay The in vivo 
assay procedure of Guillemin et_ al. (51) was used to measure 
CRF activity. A.! assays were performed in the mori.ii.g, be­
cause Guillemin and his group (50) found that the resting 
level of plasma corticoids was the lower,t during this period. 
.Male rats weighing 150-170 g. were used. Each rat was 
placed on the following time schedule : Kemuutal (4.9 mg./ 
100 g. S. V;. ) was injected in traperi tone ally at zero time. 
After tne rrt was" asleep, it was placed on an electric olanket 
in a Dox through wnich 95;6 oxygen-5# carbon dioxide was passed 
at a flow rate of 7.5 1./min. Thirty-five minutes after the 
nembutal, morphine (2.0 mg./lOO g. B. Yi. ) was injected intra­
peritoneal^'. This was a modification of Guillemin1s assay 
in which morphine was given 25 minutes after nemcutal and was 
done to assure that the rats were completely anesthetized. 
A small opening was made in the neck of the rat 15 min. after 
the morphine injection, and the sample to be tested was in­
jected into the exposed external jugular vein. All samples 
were administered in 0.3 ml. of physiological saline. 
4.3 
Exactly 15 minutes after the sample had been given, the 
animal was opened at the midline of the abdomen. The viscera 
.were lifted out, and 5 ml. of blood were withdrawn into a 
heparii.iz.ed syringe from the dorsal aorta. This operation 
was completed within 40 seconds. The blood was centrifuged 
immediate!..;' to obtain the clear plasma. The plasma samples 
were frozen until the fluorometric determination of the corti­
costeroids was done-. The interval of lo minutes after s s mole 
injection was selected because the maximal concentration of 
plasma corticosteroids has ueen found 15 minutes after stress 
• qr injection of ACT.i (48). 
During tne assay a cr ruiul record was kept of the condi-
% 
tion of each rat. If an ani...al appeared -to be awake or mori­
bund , his corticosteroid value was not included in the final 
assay results. 
The determination of the plasma free corticosteroids was 
carried out on 2 ml. aliquots of plasma according to the 
rne tnoa of Siloer ( 149) as modi lied by Guillemin (49) . A 
Farrand fluorometer was used with the filter system suggested 
by Sweat (155). 
Chloroform v.as freshly distilled over sodium carbonate 
before each determination. A deionized water sample was used 
as a reagent blank. Galvanometer readings of the water blank 
were of the order of 1.0-2.5. 
For sulfuric acid induced fluorescence of corticoids the 
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11-hydroxy group is essential and the o(,^3 unsaturated ketone 
ii. ring, A also exerts a strong influence. A 17-hydroxy group 
has little effect. Corticosterone ( cpd. 3) was chosen as the 
standard for the fluorometric determinations, because it is 
the principal steroid found in the rat. 
Two cpd. 5 standards and an internal plasma pool standard 
were used in every fluorometric determination. The internal 
standard was prepared by pooling plasma from stressed rats. 
The animals were stressed with ether anesthesia, and the blood 
was withdrawn from the abdominal aorta 15 minutes later• The 
pooled plasma was then divided into a11quots and frozen. The 
value for the corticosteroid concentration of a plasma, cool 
does not vary even after the samples have been stored for many 
months (48) . , 
The cpd. E level of the plasma pool showed good reproduc­
ibility from one fluorometric determination to another. The 
variations for three different plasma pools are listed in 
Tacle 5. 
Uninjected rats or rats injected .with physiological 
saline were introduced randomly throughout each assay as con­
trols. The CRF activity of a sample was calculated as the 
per cent increase in corticosteroids over the level of the 
combined controls. 
The sensitivity of the rat preparations was tested by 
injecting USP-ACTH in the nembut8l-morphine-blocked animals. 
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Table 5. Concentrations of .cpd. 5 in the internal plasma 
pool standards 
Kumcer of Plasma -cpd. B 
-ool determinations jug-/100 ml. 
A ' 21 32.1 + 0.7a 
B 24 49.4 + 0.9 
C 10 33.4 + 0.4 
^Standard error of the mean 
Table 6. Concentrations of plasma free corticosteroids in 
nembutal-morohine-blocked rrts after injection 
of ACTH 
Kumcer ACTH Plasma - cpd. B 
of rats mU. yKg./lOO ml. 
5 0.205 13.8 + .2.8^ 
3 0.410 27.3 + 2.5 
4 0.820 33.8 + 0.95 
^Standard error of the mean. 
With increasing doses of ACTH a graded response was obtained. 
These data indicate that the morphine-nembutal-blocked rat is 
as sensitive to ACTH as the hypophysectomized rat, for 
Guillemin et al. (48) obtained very similar values after 
injecting USF-ACTH into hypophysectomized rats. 
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Table 7. Concentrations of plasma free corticosteroids in 
the hypophysectomized rat after injection of 
ACTH (48) 
Kumcer ACTH Plasma - cpd. B 
of rats mU. /^g./lOO ml. 
6 0.2 lb.4 + l.6a 
6 0.4 27.8 + 1.6" 
6 0.8 38.z + 2.3 
^Standard error of the mean. 
ACTH assay kale r.?ts in the srme weight range as 
those used for the CRF assays were hypophysectomized by the 
parapharyngeal approach cy krs. Peggy Randolph. Twenty-four' 
hours after the opération the rats were anesthetized with 
ether. Tne sample was injected into the external jugular 
vein, and a blood sample was withdrawn 15 minutes 1^ter from 
the acdominal aorta exactly as wss done in the CRF assays. 
The concentrations of corticoids in the plasma were determined 
fluorometrically as previously. Two dose levels (1.0 mU. and 
0.c5 ml".) of USp Corticotropin Reference Standard (1.41 U./ 
mg.) were injected randomly throughout the assay, so that the 
activity of the sample could be calculated in ACT'-" units/mg. 
KSH assay Melanocyte stimulating activity was assayed 
in both intact and hypophysectomized frogs by the semi­
quantitative method of Landgrebe and Waring (83). Hypophysec-
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tomized frogs are more reliacle assay animals, because their 
melanophores do not respond to nonspecific agents. 
The frogs were placed under a light several hours before 
the assay• Then the melanophores in the web of the foot were 
checked under a low power microscope• If the melanophores 
were contracted, the frog was selected as en assay animal and 
injected with the sample• After 1 1/2 hours the size of the 
melanophores was observed ? gain and compared tc the Hogben 
i-.elanophore Index (64). On this scale increasing sizes of 
expanded melanocytes were given numbers from 1 through 5. The 
• approximate K3H activity of a sample was judged by comparing 
the size of the expanded melanophores with that obtained with 
a standard of known kSH activity. 
The ixiSH standard was prepared according to the water 
extraction method of Shizume _et _el. ( 147) except that pork 
posterior pituitary powder was used instead of beef. From 
2 g. of porcine pituitary powder 1.015? g. of standard was 
prepared. This was slightly more than twice the weight yield 
extracted from beef. Only 490 mg. were obtained from 2 g. of 
beef posterior.pituitary powder. The activity of porcine 
glutamyl- however, is 2 x 107 U./mg. but that of beef 
seryl-^B-kSH only 0-2-0.4 x 107 U'./mg. (89). The species dif­
ference in activities canceled out the difference in weight 
yield, and the two standards showed almost the same activity. 
Injections of 1.25 ytg. and 2.5 ytg. of porcine standard gave 
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melanophore index readings of 2-3 and 3-4. One unit of MSH 
activity was defined as 0.04yxg. of the standard. 
Inactivation studies 
Temperature inactivation The loss of pressor activity 
and CRF activity of synthetic lysine vasopressin was followed 
after storage for varying lengths of time at -15°C., 25°C. and 
37°C. 
pH inactivation The stability of the activities in 
acidic and basic solution at room temperature and 100°C. was 
examined. All solutions were adjusted to pH 7 before bioassey. 
Thioelycolale inactivation Thicglycolate reduction of 
crude and synthetic vasopressin preparations was studied by 
varying the concentration of thioglycolate from 1 to 600 moles 
per mole of vasopressin. 
Pepsin inactivation The conditions for the pepsin 
inactivation experiments were essentially the same as those 
used oy Royce and Bayers (126). The ratio of pepsin to milli-
units of pressor activity was 4 jx.g./cc. to 160 mU./cc. After 
the solutions had been incubated at 37°C. for 2 hours, the 
action of the enzyme was stopped by adjusting the pH to 7. 
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RESULTS AND DISCUSSION 
Continuous Electrophoresis 
Continuous electrophoresis of 
methanol extract (CE 75) 
In 1957 CRF active fractions had been prepared from crude 
posterior pituitary materials in two ways. Schelly (139) used 
paper chromatography in four different solvent systems; 
Guillemin et el. (55) obtained their D-delta fraction by a 
combination of paper chromatography end electrophoresis. Both 
of these procedures were so laborious end time-consuming that 
they were poorly suited tc large scale preparation work. In 
an. attempt to find a more efficient large scale isolation pro­
cedure continuous electrophoresis (CE) was investigated. 
The starting material was a methanol extract (96) of Kama 
product from Princeton hog posterior pituitary powder. A 1% 
solution was prepared by dissolving 1.0107 g. of methanol 
extract in 100 ml. of the electrolyte, 0.5 K acetic acid. 
Instead of keeping the electrolyte in ice the entire apparatus 
was moved into the cold room for this run. Under these con­
ditions a voltage of 600-610 V. was attained at a constant 
current of 'c3 ma. The electrophoretic fractions were col­
lected and lyophilized during the 94 nr. run. The weight 
recovery, shown in Table 8, was 71;%. 
In this experiment the pressor peak was found at fraction 
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1-4 30. c 33 0.5 
5-6 %6.4 25 2.2 
7-8 24.6 56 22-0 
9-10 2k.. 7 55 31.25 
11-12 20.B 63 3.7 
13-14 . 18.9 54 0.0 1.9 
15-16 17.0 70 0.6 2.0 
17-18 15.1 86 0.8 1.7 
19-20 13.2 ill 0.45 1.6 
21-24 11.3 74 0.45 
z5-3'c v 7.5 100 0.5 
9-10. The in vitro CRF assays were performed by Dr. Roger 
Gui11emin at Baylor University College of Medicine, Houston, 
Texas. In the expression of the in vitro results a potency 
of 1-0 meant that there was r.o increase in ACTH secretion over 
tne control pituitary flfsK and therefore no CRF activity. 
A potency of 2.0 was equivalent to the activity of Fraction D 
of Guillemin et al- (58). The four CE fractions on the anode 
side of the vasopressin peak (F13-14, F15-16, F17-18 and F19-
20) appeared to be almost as potent as Fraction D. Ko CRF 
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assays were carried out on the electrophoretic fractions which 
had pressor activity, because this was an attempt to show sep­
aration of the two activities. 
Paper chromatography in butanol:acetic acid:water (4:1:1) 
snowed that all the electrophoretic fractions were gross mix­
tures of ninhydrin-positive materials. 
Continuous electrophoresis of countercurrent 
distribution fractions (CE 208-2.3) 
The results from the previous continuous electrophoresis 
experiment indicated that low pressor, CRF active fractions 
could be obtained with this procedure. In 1959 after an in 
vivo CRF assay was set up in our own laboratory, the continuous 
electrophoresis separation was reinvestigated in order to test 
the fractions in our assay. 
A cleaner starting material was obtained by using samples 
from a countercurrent distribution (CCD 39) of Kamm product in 
butanol:acetic acid:water (4:1:5) (86). Because Schally et 
al. (144) had reported that CRF had an Rf value slightly high­
er than lysine vasopressin on a paper chromatogram in the 
butanol:acetic acid:water system, the leading edge (Tubes 2 
and 3) of the CCD 39 pressor peak was used. The material from 
Tube 2 had 9.62 U./mg. pressor activity and Tube 3 had 4.22 
U./mg. 
For CE 208-3 a sample of 0.4464 g. of CCD 39-Tube 3 was 
dissolved in 0.5 N acetic acid. The weight and pressor 
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results for this electrophoresis run are shown in Table 9. 
The weight recovery was 65/v and the pressor 6'c%-
In this electrophoresis the pressor peak had shifted to 
F15-16. However, the starting material was different from ' 













11-.12 84.8 1.03 
13-14 35.8 . 19 .3 
15-16 12.9 28.2 
17-18 12-9 0.53. 
19-20 17.9 0.44 
21-22 19.5 0.64 
23-24 21.1 0.03 
25-26 0.4 
27-28 8.2 
that used in the 
was carried out 
previous run 
at room temper 
(CE 73), and the electrophores: 
ature with the electrolyte in , 
ice bath. Under these conditions 30 ma. of current gave only 
530-540 V. 
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Identical conditions were used for CE 208-2 which wss run 
on 1.0688 g. of CCD 39-Tuce £. Table 10 shows that the pres­
sor peak again occurred at F15-16. The greater pressor activ­
ity of this fraction reflects the. higher activity of the 
starting material. The weight recovery was 69;/ for CE £08-2• 
Table 10. V.'eight and pressor results of CE 208-2 
Weight . Pressor'activity 




7-6 38.1 <0.02 
.2-10 1^4.0. <0.02 
11-lc 159.6 0.5 
13-14 92.0 17.4 
15-16 5%.3 50.0 
17-18 46.3 6.7 
19-cO 42.8 1.1 
%1-kà 42.9 l.%5 
23—ic.4 43.3 0.6 
%5-26 17.1 1.1 
%7-cS 30.4 0.8 
29-30 13.3 <0.02 
31-32 7.9 
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but only 46.5;c for the pressor activity. Since £08-3 and. 
&08-2 were run under identical conditions, the reason for the 
lower recovery in CE 208-2 is unknown. Perhaps there was some 
inactivation during the.lyophilizotion of the samples. 
The CRF activities of fractions from CE 208-2 were 
measured in nemcute.l-morphine-bioeked rets. The results are 
given in Table 11. All the samples were assayed rt pressor 
dosages below-60 mU., the threshold value at which Guillemin 
et al. (54) had stated that lysine vasopressin began to show 
inherent CRF activity. Although ihe pressor dosages were low, 
the peak of the CRF potencies appeared to coincide with that 
of tne pressor activities. Fraction 15-16-gave e 140/: increase 
in plasma corticosteroids over ^ controls • at 0.6ytig. per injec­
tion. 
As in the previous electrophoresis run. the fractions on 
the anode side of the pressor peak were low in pressor activ­
ity cut snowed CRF activity as if there had been some separa­
tion of vasopressin and CRF. Because ACTH also will release 
corticoids in the CRF essa-, the ACTH content of Fbl-22 was 
examined. The results are shown in Table 12. Although these 
assays were only roughly quantitative, F21-22 eppeered to heve 
approximately 0.02 U. of ACTH per mg. In the CRF assay 45y%g. 
of F21-22 were injected. This would be equivalent to 0.9 mU. 
of ACTH which would account for almost all of the CRF activity 
of this fraction. 
ïacle 11. CRF assays of fractions fror;. CE 208-2 
Pressor Pressor Plasms - cpd. B 
activity dose >*p;./lQ0 mi. Cpd. B % 







 (5)8 8.1 + 0.5° (3) .9.8 +_ 
CO w
 1.7 20 
15-16 50.0 0. 6 30.0 (5) e.i + 0. 5 (5) 
C» i—1 
+_ 2-1 11.3 1.40 
17-18 6.7 c .4 16 .1 (4) 7.4 2.1 (3) 25.1 + 4.8 17.7 240 
19-20 1.1 2.4 2.6 (4) 5.8 + 1.5 (4) 4.8 + 0.9 0.0 0 
H 45.0 49.5 (4) 7.4 +_ 2.1 (5) 35.4 + 2.8 28.0 380 
ici— 'C,'CJ 1.25 45.0 56. c. (3) 6.7 jv 1.7 (3) 31.6 ±_ 1.3 25.1 3 75 
2o—L.4 0.4 45.0 18.0 (4) 5.8 4- 1.5 (5) IB. 2 + 2.4 12.4 215 
%5-26 ' 1.1 45.0 49.5 (4) 5.8 + 1.5 (4) 27.9 + 4.0 22.1 380 
27-28 0.6 45.0 36.0 (5) e .o <S. 5 (5) 12.7 +. 1.4 4.7 60 
aKumber of rats . 
^Standard error of the mean. 































aNumber of rats. 
°Standsrd error of the mean. 
Plasms - cpd. B 
^ng./lOO ml. 
Contro1 Sample 
(5)^3.45 + 0.3 
(4) 2.4 + 0.1 
(3) 18.1+0.5 
(3) 5.1 + 1.0 
(4) 29.4 + 1.8 
(3) 9.7 + 0.9 
(4) 26.7 + 2.6 
(4) 8.1 + 2.4 
(3) 23.6+5.8 
(4) 13.1 + 3.2 
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Ko melanophoretic activity was observed in F21-22 after 
injection of 2-5yWg./dose in the in vivo frog assay of Land-
grebe and 'Waring (83) . 
Continuous electrophoresis of countercurrent 
distribution fractions (CE 225 .end CE 226j 
The starting material for these electrophoresis runs had 
been fractionated previously by countercurrent distribution 
in ÛWO solvent systems. .Ksmm product was distributed in 
butanol: acetic scid:wa.ter (4:1:5) ( CCD 47). Then tubes 2 and 
o of CCD 47 were submitted to countercurrent distribution in 
sec-cutanol:0.bp trichloroacetic acid (1:1). Four separate 
distrioutions (CCD 48, 45, 50 and 51) were made to provide 
enough material for electrophoresis. The pressor peak of 
each CCD wss located by assay, and the tubes- from the descend­
ing part of the pressor curves were pooled (66). 
CE 225 was run on 0.6108 g. from" CCD 48 and CCD 49. The 
pressor activity of the material from CCD 48 was 9.7 U./mg. 
A pooled sample from CCD 50 and J CD 51 of 0.5-338 g. was used 
for CE 226. The weight and pressor results for CE 225 and 
CE 226 are listed in Tacle 13. The weight recovery was 67/3 
for the combined experiments. The highest pressor activity 
was found in F15-16 in both runs. 
In order to compare the CRF activities of the continuous 
electrophoresis samples, F13-14 of CE 225 was arbitrarily 
chosen as a standard. One milliunit (CE mU.) of CRF activity 
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Tacie 13. V»eight and pressor results for CE 225 end CE 226 
Weight Pressor activity 
Fraction mg. U./mg. 
CE 225 
11-12 36.4 2:0 
13-14 63 .3 17.7 
15-16 ' 49.4 50.0 
17-18 39.3 12 « 4 
19-20 40.0 1.6 
2I-22 46.4 1.4 
23-24. 31.5 1.1 




7-8^\ 25.5 0.04 
9-10* 47.-5 ' 0.10 
11-12 c7.7 4.S 
13-14 54.3 47.6 . 
15-16 4-3.1 76.0 
17-18 32.5 10.1 
19-20 29.5 0.13 
2I-22 3-3.8 1.1 
23-24 27.6 
25-%6^ . 19.4 
27-28% 16.8 1.2. 
29-30^ 19.9 1.9 
0These fractions were oocoined from CE 225 and CE 226. 
was defined as the increase in cpd. B/lOO ml. plasms over the 
controls given by lyug. of F13-14. The results of an in vivo 
CRF assay of F13-14 at dose levels of 0.9, 1.8, 3.6 and 7.2 
yxg. are listed in Table 14a. The log dose response curve ob­
tained from the CRF date is drawn in Figure 1. 
An ACTH assay of CE 225, Fl-3-14 in 24 hour hypophysec-
Table 14a. Assays of CE 225 (F13-14) for CRF activity and ACTH activity 
Pressor Pressor Plasma - cpd. B 
activity dosage ./lOO ml. . Cpd. B 
Sample ywg ./inj. mU./mg. mU./in j . Control Sample incr. 
1-3-14 0.9 17.7 15.95 (4) S4.25 + 1.2b (4) 8 .3 + 1.7 4.05 
1.8 ii . 31.9 II (4) 11.6 + 1.3 7.35 
3.6 ii 63.7 (4) 5.25 + 1.1 (4) 21.8 + 1.3 15.55 
?.% II 127.-3 n (4) 30.4 + 1.6 25.15 
ACTH 0.25 rnU. 
1.0 mU. 










1-3-14 0.9 17.7 • 15.95 II (5) 2.9 + 0.2 0.0 
•3 .6 II 63.7 . II (8) 4.0 + 0.4 1.15 
. 
8Kumber of rrts. 
cStanderd error of the mean. 
Figure 1. Increase in plasma corticosteroid ii. nembutal-morphine 
blocked rets due to CE 225, F13-14 
25.0 








1.0 0.1 2.0 3.0 4.0 5.0 6.0 70 8.0 10.0 
CE MILLIUNITS (CE 225, 13-14) 
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tomlzed rats also is shown In Table 14a• This fraction had 
negligible ACTH activity. 
The CRF assays of the fractions of CE 225 were all per­
formed at pressor levels of -30 mU. per injection. This was 
the level recommended by Schally and Guillemiri (141) as free 
from CRF activity due to vasopressin. The results of these 
assays are shown in Table 14b. 
The CE units for CRF activity were calculated using the 
provisional CE 225, F13-14 standard. A graph (Figure 2) of 
the pressor activities and the CRF activities of the frac­
tions.. from CE 225 demonstrates that the peaks of both activ­
ities occur at F15-16. Continuous electrophoresis did not 
separate the two activities. It was also noted that many of 
the fractions gave similar per cent increases in corticoids 
at the constant pressor dosages of 30 mU. 
Continuous electrophoresis of a countercurrent 
distribution fraction (CE 236) 
Another continuous electrophoresis run (CE 236) was made 
on material from tube 1 of the countercurrent distribution 
(CCD 47) in butanol:acetic acid:water (4:1:5) of Kamm product. 
This starting material had 6.3 pressor units per milligram; 
4.6407 g. were run under the same conditions as CE 208-2,3. 
The weight recovery was 72^. 
The MSH activities of these fractions were tested with 
the .in vivo frog assay of Landgrebe and Waring (83) . Because 























1--12 2.0 15 30 (4)a6.25+1.5° (4) 26.6+2.8 20.35 5.5 0.37 330 
13-14- 17.4 1.8 31 (5) 15.3+1.8 9.05 1.85 1.0 145 
15-16 50.0 0.6 30 (5) 15.45+2.3 9.20 1.87 3.12 150 
17-18 Ik,»4 2.4 30 (5) 6.2+0.5 (5) 22-2+2.3 16.0 3.6 1.5 260 
19-&0 1.6 16.0 29 (5) 17.6+0.7 11.4 2.3 0.13 ISO 
21-22 1.4 21.0 29 ( 5) 16 . 2+2 . 7 10.0 2.03 0.10 160 
23-24 1.1 27.0 31 (4) 5.3+0.5 (4) 19 .6+2 . 2 14.3 3.08 0.11 270 
25-26 0.8 36.0 . 22 (5) 18.2+1.4 12-9 2.67 0.08 240 
27-28 1.2 • 24 .0 29 (5) 13.3+1.7 8.0 1.7 0.07 150 
aKumber of rats. 
^Standard error of the ween. 
Figure 'CJ. Pressor and CRF activities of continuous electrophoresis 
fractions (CE 225 and CE 226) 
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this assay was only semiquantitative, the MSH activities were 
only approximations. The weight, pressor and IvSH results for 
CE 236 are shown in Table 15 snd graphed in Figure 3. The 
peak of pressor activity was at F15-16, end the peek of KSH 
Table 15. Weight, pressor snd kSH results of CE 236 
Weight Pressor sctivity KSH activity 
Fraction iLg. U./mg. U./mg. x 10^ 
1-2 11.1 
3-4 11.0 
5-6 16.0 1.6 
7-8 120.7 0.08 3.2 
9-10 415.5 0.10 4.25 
ll-lfc 838.9 0.4 40 
13-14 702.3 12.9 53.5 
15-16 459.8 36.2 16.25 
17-18 242.5 27.7 12.5 
19-20 106.7 5.9 
21-£2 127.6 0.16 





Figure 3. Pressor end IMSH activities of continuous electrophoresis 



















5-6 7-8 9-10 11-12 13-14 15-16 17-18 19-20 21-22 23-24 25-26 27-28 29-30 31-32 
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activity was at F13-14. Ko CRF assays were performed on the 
fractions of this run. 
Additional experiments on continuous 
electrophoresis fractions 
Continuous electrophoresis smaples-were submitted to 
further fractionation by other methods to determine if the 
CRF activity could be separated from the vasopressin. These 
experiments were carried out by Eugene Lazzari and his assist­
ant' and are described in detail in his Ph. D-. thesis (36) . 
Paper chroma to&rsphy of CE 225, F17-le, (PC-1<:0)' An 
EDTA-washed Whatman V.o . 1 paper was streaked with a sample of 
CE 2^5, F17-16 and developed in butanol:acetic'acid:water 
(4:1.: 5). The chroma to rram was cut into neg...ents which were 
eluted with l;'j cold acetic acid. When pressor and CRF assays 
were performed on tne eluates, the highest concentrations of 
pressor activity and CRF activity were found at the same Rf 
of 0.25. 
Ion exchange chromatography of CE 225 and 226. F15-16 
(IRC 50-19) The pressor peak (F15-16) was chromatographed 
on IRC 50 cation exchange resin. ' When the column was eluted 
with 0.5 ii ammonium acetate at pH 6.4, the vasopressin peak 
came off at 3.2 holdup volumes. The maximum CRF activity 
also was found in this- fraction. ' 
The pressor and CRF peak from the IRC 50 column then was 
submitted to countercurrent distribution (CCD 52) in 0.5$ 
trichloroacetic acid equilibrated v.dth en equal volume of sec-
Gutanol. These CCD fractions were assayed twice for CRF on 
different days. Both essays gave the same result. The peak 
of CRF activity coincided with the pressor peak. 
A sample from the pressor and CRF peak of the IRC 50 
column also was streaked on paper. The chroma togram (PC 121) 
was developed in acetone:water (3:2 v/v), and segments ;-f the 
paper were eluted with 0.1;; acetic ?cid. Assays, of the eluted 
samples again showed- the CRF activity in the same location as 
the pressor activity et an'Rf of 0.77. 
For these•experiments the CRF assays were crrried out 
on samples with 50 ml", of pressor activity per injection. At 
this pressor dosare similar increases in cpd. 5 over controls 
were noticed for almost ell the samples as say-.-d. This obser- ' 
vation and the feilure to achieve seperetion of CRF activity 
from vasopressin by any of the fractionation procedures 
prompted an investigation-of the inherent corticotropin-
releasing activity of vasopressin. 
Corticotropin-releasing Activity of 
Synthetic Lysine Vasopressin 
du Vigneaud synthetic lysine vasopressin 
Synthetic lysine vasopressin was chosen to test the 
corticotropin-releasing ability of vasopressin in the.in vivo 
CRF assay, with synthetic materiel there was no possibility 
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of .contaminants with CHF activity which might ce present in 
vasopressin isolated from pituitary sources. 
The synthetic vasopressin (Ji-i V 66/16) had been prepared 
in the laboratories of Dr. V. du Vigneaud. The entire sample 
was weighed, dissolved in deionizeu water and assayed for 
pressor activity. Two pressor assays gave ah average value 
01' COL U./mg. Tne solution was then divided into aliquots, 
iyophilized and stored in a deep freeze. Assays for CRF were 
carried out on solid sampler which had been diluted in physio­
logical saline just before each assay. 
The results from the injection into nemcutal-morpnine 
clocked rats of four dose levels of synthetic lysine vaso­
pressin • re' :„ive.. in Tacle lc. The controls include both un­
infected rats and saline injected r^ts, cecnuse statistical 
analyses of the two types of controls showed no significant • 
difference between them - At the lowest dosage of vasopressin, 
8.4 mU•, the slight increase in clasma-cpd. 5 was insignifi­
cant. At the three higher doses, 16.6 mU., 33.5 mTJ. and 57 
ml'., a significant increase in cpd. B was found in each case. 
Tne data for these three dose levels were submitted to anal­
ysis of variance. A value of 11.4 was obtained for F sig­
nificant at the 0.1;é level. 
Figure 4 shows, the regression line calculated from these 
data. The regression equation was y = -134 + 14.5(x). The 
per cent increase in plasma corticosterone is plotted versus 
Table.16. Effect of au Vigneaud synthetic lysine vasopressin on the plasma 
cortlcosterone of rats 
Pressor Plasma - cpd. B % increase 
dosage MK . /100 ml. Cpd. S o over 
mU./inj. Control Sample increase p value' control 





 (10) 6.5" + 1.1 O.c' • .8>p>.7 - -
16.8 (18) 8.% + 0.7- (19) 11.4 0.7 •3.L • 01>p ? . 1 39 
do. D (10) 8.1 + 0.8 (9) 14 . 7 + 1.4 S.6 <•001 81 




 <•001 125 
ap calculated from t on values for plasma end. £ in contrôle and in sample 
injected rats. 
CI\ umber of rats. 
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Figure 4. ACTH-relessing activity of du Vigneaud synthetic 
lysine vasopressin in nembutal-morphine blocked 
rats 
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tne log of the vasopressin dose. The cars indicate the 
standard errors of the means at the three dose levels. 
kcCann and Fruit (95) investigated the ACTH-relessing 
activity of synthetic vasopressin, out they used rrts with 
acute hypothalamic lesions and depletion of adrenal ascorbic 
aciv. as the index of ACT H release. Vvi th their assay system 
lysine vasopressin gave a linear log-dose versus response 
curve from 100 mU. to 1000 n.U. --her. Guillemin e.t £l. (51) 
tested highly purified lysine vasopressin (£67 U./mg.) in the 
nembutal-morphir.e blocked rat, no significant increase in 
plasma-cpd. B Was found at any dose level ce low SO ml1. Above 
60 mU. a large discharge of ACT4 was observed increasing 
linearly with the log-dose of vasopressin. 
Rather than indicating a threshold at 80 mu., the present 
data extend the line• r response curve of ACTz release versus 
log dose of vasopressin down to dose levels between' 17.8 to 
67 mU. of vasopressin. Synthetic lysine vasopressin is active 
in releasing ACTH at levels of .05 to -28y/g. The cortico-
tropin-relea sing activity of lysine vasopressin exceeds that 
reported by Schelly et al. (140) for their purest preparations 
of o^-CRF and ^ -CRF. The minimum effective dose in the in 
vivo assay of ^- CRF was b-3 yxg. and of (3-CRF was 0.1 . 
After the high inherent corticotropin-releasing activity 
of lysine vasopressin was discovered, a re-evaluation was made 
of all the assays which had been carried out during the 
unsuccessful CRF isolation work. According tu the synthetic 
lysine vasopressin data when tnese samples were essayed at 
•30 mU. of pressor activity an increase of 6.1 ytg. of c - d. B 
over tne level of the controls was due to the CRF activity of 
the vasopressin present. If s (3 -CRF was also present in 
these samples, the additional CRF activity should ce apparent 
in the assay results. Ta'cle 17 lints the assays performed on 
samples from tne series of experiments wnich started with 
CE c&6. For the £1 assays an ever; ge value of 6.5 was ob­
tained for the controls and 15.c for the samples. This gives 
an increase in cpd. £ of .G.Syng./100 ml. pl??ca. In view of 
t.ie wide variation in controls end large s tan- ard errors of 
the means which occurred in many of these in vivo essays, this 
velue shows rem.-rk.ecle agreement with the increase in cpd. 2 
given cy synthetic lysine vasopressin. It appears that essen­
tially all the CRr activity of these sa... les was due to their 
pressor content. The only sample not included in these cal­
culations was IRC 50-19, tube 1. This sample had MSH activ­
ity and therefore, its high CRF activity was probably due to 
both ot-CRF and vasopressin. If (3 -CRF exists in porcine 
posterior pituitary preparations, it must have been inacti­
vated early in the isolation procedure or it must be a weaker 
CRF than vasopressin. 
Table 17. CRF assays of fractions obtained in purification procedure 
- Pressor Pressor Plasma - cpd. B 
Fraction U./ml. dosage ./1O0 ml. Cpd . B % 
or tuce y*g-/inj - o r mg . * mU./inj . C ontrol Sample incr • incr. 
CZ 226 P V\ (5) 13-14 1.8 17.4* 31 ( 4 ) 6.3+1.5 15.3+1.8 9.05 145 
15-16 0 6 50 . 0* 30 (4) 6 .3+1. 5 ( 5) 15 . 5+2 . 3 9.2 150 
PC lfcO 









10.8+0.4 3.5 50 
IRC 50-IS 
(5) 1 60.0 0.48" 30 (5) 4.6+0 .6 24.6+1.3 20.0 435 
2 3 .0 8.0* 24 (3) 5.7+0.8 5 (3) 11.75+0.3 6.05 108 
3 0.17 160.0" 27 (5) 4.5+0.6 (5) 13.1+%.5 6.05 185 
IRC 50-19 
Peak. -3 
(4) 66 49 29 • (4) 6.0+0.9 12.3+2.0 6.3 105 
91 66 31.5 (4) 6.0+0.9 (4) 11.1+1.2 5.1 85 
96 92 30 (4) 6.0+0.9 (4) 8.3+2.8 2.3 38 
96 91 30 (5) 4 • 6+ 0.4. (5) 2 .0+1.3 4.75 95 
PC lîdl 
(5) 20 0.7 30 (2) 6 .4+ 0 .6 8.4+0.8 2.0 31 
22 4.3 30 (4) 7.6+0,4 (4) 12.25+0.9 4.65 61 
24 0 . L 30 (2) 6.4+0.6 (4) 16.0+2.5 11.6 ' 181 
(4) 7.6+0.4 (•3) 11.8+1.6 4.2 55 
ar;uriiber of rats. 
•^Standard error of the mean. 
Table 17• (Continued) 
Fraction 
or tube ./inj . 
Pressor 
U./ml. 
or nr, .* 
Pressor 
do s ag e 








incr. incr . 
CCD 52 
(7/29/60) 
6.6 (CPIC.; (3) 45 10.6 •30 12.0+1.65 5.4 82 
47 16 .0 b9 11 (4) 12.7+1.3 6.1 92.5 
51 22-0 28 M (3) Ik, • 3+1.4 5.7 86.5 
55 lo.O •30 II (3) 11.0+2-8 4.4 66.8 
59 4.4 •30 It (4) 11.6+0.6 5.0 76 
(8/19/60) 
(4) 7.1+1.0 (3) 7.0 43 10.6 30 14.1+ 2.4 98.5 
47 16.0 •30 it (3) 19.5+2.3 • 12.4 175 
51 %2.0 •30 H (4) 17.9+2-4 10.8 152 
55 15.0 31 ii (4) 17.6+4.7 10.5 148 
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Sandoz synthetic lysine vasopressin 
Another preparation of synthetic lysine vasopressin was 
donated cy Sandoz Pharmrceuticals Company. The arterial was 
received in solution in s>.. àled vials. Each vial was stated 
tJ contain 10,000 mU. of pressor activity In 1 cc. of saline. 
Two assays in our laboratory gave 9,620 mU./cc. and 10,540 
mU./cc. with a mean value of 10,050 mU./cc• The corticotropin-
releasing activity of this preparation was tested in the In 
vivo assay. The results at i.ine different pressor levels are 
shown in Table 18. 
An analysis of variance of these data gave a value of 3.5 
for F, significant at tne 0.5/= level. Lie regression line 
calculated for Sandoz lysine vasopressin vas y = -250 + 214(x). 
The regression coefficient was significant at the 0.1. level. 
Figure 5 compares the regression line for Sandoz vasopressin 
with the line obtained for the du Vigneaud vasopressin. Both 
synthetic lysine vasopressins show CRF' activity in the same 
range of pressor dosages. The greater variation of controls 
and. sample values in the bio as says of the Sandoz vasopressin 
may account for tne difference in the slopes of .the two lines. 
Tne log-dose response curve obtained with the du Vigneaud vaso­
pressin is probacly the more reliable. 
















(8) 8 9.5 + 0.7° (7) 10.5 + 0.6 1.0 10. 5 
£4 (7) 9.3 + 1. (10) l£.3 + 1.5 3.0 . 32 
£9 (5) 8 • 5 + 0.8 (6) 17.4 + 3.1 8.9 105 
30 (7) 9 .6 + 1-1 (9) 13.5 + 1.3 3.9 41 
43.5 (8) 10.3 + 1.0 (9) 17.6 + £.6 7.3 71 
47 (6) 10.65 + £.0 (6) 20.0 +_ 1.85 9.15 84 
53 (6) 9 . 7 + 1.1 (7) £1.0 + £. 6 11.3 116 
56 (  &)  8.5 + 0.6 (7) 19.£ + 3.6 10.7 1£6 
70 (7) 11.6 + 1.05 (B) £7.6 + £.35 16.0 138 
aNumber of rats . 
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Figure 5. ACTH-releasing activities of du Vigneaud and 
Sandoz synthetic lysine vasopressins 
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ACTH assay of synthetic lysine vasopressin 
The increase in plasma corticoids in the in vivo assay 
could have been the result of a direct ACTH-like effect on the 
adrenals by vasopressin. In order to test this possibility 
du Vigneaud lysine vasopressin was injected into hypophysec­
torized rats. A dose' of 67 mU. was used. Tills was the highest 
dose that had been injected into the nembutal-morphine blocked 
rats. The results in the two types of assay animals are com­
pared in Tacle 19. In the 'hypophy sectomized rats the control 
Table 19. Effect of synthetic lysine vasopressin in 




Plasm? - cpd. B 
yx£ ./100 ml. . Cpd. B 
Animal mU./dose Control Sample increase 
i.em.-mor. 67 (7)a8.1+1.4b (10) 18.2+1.4 10.1 
Hyp. 67 (11) £.4+0.1 (9) . £.5+0.1 0.1 
"'Number of rats. 
^Standard error of the mean. 
values were lower, but the injection of synthetic vasopressin 
gave no increase in cpd . B over the controls. 
Previously Hilton et si. ( 6-3) obtained an increase in 
adrenal venous hydro cor tisone during direct arterial infusion 
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ol' vasopressin into the adrenals of hypophysector:!zed dogs. 
Royce and Sayers (125)- found that large intravenous doses 
(<;.5-5.0 U.) of purified arginine vasopressin or of commer­
cial Pitressin depleted adrenal ascorbic acid in hypophysec-
tomized rats. However, in the hypophys-:.cton!zed guinea pig 
5 u. of Pitressin injected intraperitoneally had no effect 
(148). 1'icCann and Haberland (96) were un^cle to demonstrate 
an extrapitultary effect of vasopressin in a decapitated rat 
with a dose of 500 mU. of Pitressin. Guillemin et al. (48) 
found no increase in plasma corticosteroid levels with intra­
venous injections of 300 mU. of arginine 'vasopressin into 
hypophysectoadzed rats. Lower doses of vasopressin injected 
intravenously s p.. erred to have no direct effect on the 
adrenals. 
The results with tne du Vigneaud vasopressin support the 
latter, findings and indicate that the observed increase in 
corticoids after injection of synthetic lysine vasopressin is 
a true CRF effect.' 
kSH assay of synthetic lysine vasopressin 
Tne Sandoz synthetic lysine vasopressin was tested for 
kSH activity in the in vivo frog assay of Landgrebe and Vlaring 
(83). Four dose levels ( 25 ml'., 100 mTJ., 400 mU. and 800 mU.) 
were injected. Ko KSH activity was observed. 
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Pressor and Corticotropin- r v.leasing Activities 
of Synthetic Lysine Vasopressin after 
Inactivetion by Various Agents 
Temperature Inactivatlon 
One of the problems in this study was that it was almost 
impossible to do botn the pressor end the CRF bioassays at the 
same tine. The pressor determination on the CRF sample was 
xuade the afternoon fo.L lowing • a. CRF assay, if possible, but . 
often c4 - hours earlier or later. Sometimes, if the pressor 
ret or rats gave poor r suits, there was an even longer period 
of time between the two ass-sys. Therefore, an investigation 
was made of the stabilities of the pressor and corticotropin-
releasing activities under-various temperatures and storage 
conditions. 
In one experiment solutions of du Vigneaud vasopressin, 
which had been stored in the freezer for two to five weeks, 
were pooled. The pressor assay of the pooled solutions- showed 
a loss of 28;* of the original pressor activity. This solution 
then was left at room temperature for 4c hours. After this 
treatment the pressor activity remained the same. The solu­
tion was frozen and thawed three times in the next 48 hours, 
left at room temperature for 43 hours and then heated in an 
oven at 37° C. for 26 1/2 hours. At this time it had lost 
23% cf its pressor activity. Table 20 summarizes these re­
sults . 
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Table 20. Inactivation of synthetic vasopressin by storage 
and temperature treatments 
Pressor Plasma - cpci. B )° incr. 
activity xp:7100 ml. ;» from 
Treatment mU./dose Control Sample incr. graph 
Lone 67 . (7) a8 .1+1 .4b (10) 18 • c+1 • 4 lb5 — 
Freezer 
inact. 
t-5 wits. 46 (b) 8 . b+ 0 .9 (6) 14 .7+1.0 72 ' 104 
Room temp. 
4s hrs 48 (6) 7 .6+1 .0 (7) 14 .4+0.8 69 104 
37° C. 
bô l/c hrs. .57 (5) V .•5+0 • 5 (?) 14 .5+1.3 170 165° 
aKumcer of rats. 
r Standard error of the mean. • 
cTsken from, i; ra.;h Kith 5.8 controls. 
The loss of CRF activity appeared tc parallel the loss 
of pressor activity under all these treatments. The last 
column in the tscle gives the value taken from the graph of 
per cent increase in cpd. B versus the log-done of du Vigneaud 
vasopressin (Figure -3). This value represents the percentage 
increase that would be expected from the mU. of pressor activ­
ity injected. T:ie experimental per cent increase was lower 
than the expected value in each case, but the small difference 
was prooacly a reflection of the variations encountered in the 
pressor and CRF assays rather than differential destruction of 
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the activities. 
Another du Vigneaud vasopressin solution which had been 
frozen for seven weeks retained only 55/- of its original 
pressor activity. There was no loss of activity after 46 
hours of incubation at -37° C . , 'but after an additional 50 
hours only 60;« of the activity was still present. Table 21 
shows these results. Again the loss of CRF potency was con­
sistent with the destruction of pressor activity. 
Table 21. Inactivation of synthetic vasopressin at -15° C. 











Treatment Û.U ./dose Control Sa mple incr -, graph 
Ko ne 57 
Freezer 
inact. 
7 wks. 37 
37° C. 
46 hrs. 37 (10)87.6+0.5° (7) 13 .3+1 • 5 71 c8 
37° C. 
116 hrs. (6) 6.9+0.9 (4) 10.0+0.6 55 55.5 
aftumbe r of rats. 
DStand erd error of the mean. 
These experiments indicrted that both pressor and CRF 
activities were relatively stable for several days. There­
fore, the pressor assay could be performed within a dey or 
two of the CRF assay with accurate results. However, there 
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we s s slow loss of coth activities even when the samples were 
stored in the deep-freeze, end samples should be re,assayed if 
frozen more then one to two weeks• 
Acid and base inactivation 
The inactivation of vasopressin in acidic and basic solu­
tions was also studied. At room temperature the pressor 
activity apperred to be fairly stable for long periods of time 
ix. either a weakly acidic or casic solution. After IS hours 
at pH -3 a solution of du Vigneaud vasopressin, whicn origin­
ally assayed lc3 m'J./cc., lost only 19.. of its pressor activ­
ity. In alkaline solution tne pressor activity was constant 
for hours. Tacle 22 show's these results. 
Tacle 'c'c. Stability of pressor activity in alkaline 
solution at room temperature 
Pressor 
Solution Time sctivity Inactivation 
no. pH hrs. mU./cc. 
70 -- 0 200 
73 11.5 1 196 2 
74 " 5 3/4 172 14 
75 " 12 . 193 35 
76 " 24 194 3 
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The very slight variation in loss of activity r..ey be due 
to the fact that a separate dilution of Sandoz vasopressin was 
prepared for each time period. Each solution was neutralized 
to a pH of 7 cefore the sa.ii.pie was injected into the pressor 
rat. 
Sideman and So eel ( 14-8) isolated a fraction from Pitres­
sin that released ACTH in the guinea pig. They concluded that 
it was vasopressin, end part of their supporting evidence was 
that mlid acid end alkaline-hydrolysis altered-the pressor 
activity and the CRF activity of the fraction to the same 
extent. 
Sandoz vasopressin wrs hydrelyzed under conditions .sim­
ilar to those used cy Sidemar.- end Socel. Physiological saline 
was acidified to a pH of l.ib with hydrochloric acid. The • 
acidic solution of 200 m'J./cc. of Sandoz vasopressin was pre­
pared and placed in a coiling water 'c th . After 30 minutes 
the solution was immediately cooled in ice water, and the p:'i 
was adjusted to 7.1 for injection. The alkaline solutions 
were handled in the same manner except that the pH was ad­
justed to 11.5 with sodium hydroxide, and one solution was 
left in the coiling water cetn for 10 minutes end another for 
'cQ minutes. The effects of basic end acidic hydrolysis on 
the corticotropin and pressor activities of synthetic lysine 
vasopressin are shown in Table £3. Sandoz vasopressin was 
much more resistant to acidic then be sic hydrolysis. However, 
Tacle 23. Effect of mild acid and alkaline hydro lysis on pressor and CRF 



















Ko ne 0 60 (6) a  6 . 5 +  0. 9 f c  (?) 24.9 + £.5 193 1E0 
pH 1-2 30 28.5 (6) 8.5 + 0.9 (6) 1-3.4 + 0.9 58 51 




aKumber ol' rets. 
^Standard error of the mean. 
under both conditions tne destruction of CRy activity parallel­
ed the decrease in pressor activity. 
Thiofc-lycolete reduction of vasopressin 
Thio&lycolate reduction of continuous electrophoresis 
ores nor fraction (CE bOS-2. F15-16) The effect of thio-
giycolfte reduction on pressor activity v;pp studied first on 
a crude electrophoresis sample. This fraction (F15-16) v;as 
tne pressor peak of CE c08-c and had a pressor activity of 
50 'J ./mg. 
A 0.05 I-, solution of thioglycolcte ar, prrp-^rec, end the 
pH iv a s adjusted to 7.y. Then £.5 of F15-1S were- dissolved 
in l• 5 «.1 • of the' thioglycolrte solution. The calculated 
molar ratio '.as l?5 moles of thioglycolr te to one of lysine 
vasopressin. Every ten minutes a sample v:as taken from the 
thioglycolr te solution and injected into the dicenamlne-' 
clocked rat. At the beginning of the experiment there v;as a 
rapid c.e struct ion of pressor activity, and SO,-- had been lost 
after two hours. At the end of four hours S71 had been 
destroyed. A plot of the inactivation versus ti...e has been 
prepared in Figure 6. 
Thioelycolate reduction of synthetic lysine vasopressin 
Thioglycolate reduction of synthetic lysine vasopressin was 
attempted under many different conditions of concentration 
and pH. A slow and reproducible method of pressor inactiva-
1100 
HOURS 
Figure 6. Thloglycolate inactivation of continuous electrophoresis 














tion was sought in order that the effect of disulfide bond 
rupture on the ACT'H-relea sing activity could ce more care­
fully investigated. 
Tacle 24 snows the results of experiments in which the 
numcer of moites of thloglycolate per mole of vasopressin was 
progressively increased. No adjustment was made ir. the pH of 
the solution. 
Tacle l4. Effect of varying concentrations of thloglycolate 







Plasma - cpd. 3 
./100 ml. 




1:0 ne 51 
1. 'cb 46 (6)aH.0+1.1° (?) -c'c.6+3.3 • 105 102 
50 o' 45 
150 /v 46 (?) 8.5+1.4 (5) 20.1+^.5 113 102 
£Nuiucer of rats. 
^Standard error of the mean. 
' Trie last two pressor assays were not reliable except as 
approximations, cut it was clear that neither pressor nor CRF 
activity had been destroyed in these experiments. 
The effects on the pressor activity of higher concentra­
tions of thloglycolate arid adjustment of the pH to 6.5 or 8 
are shown in Taule 25. The pressor activity vas destroyed 
only after 96 hours with 500 moles excess thioglycolate et 
pri 8. During these experiments s solution of thloglycolate 
alone at the same concentration as in solution 13 was injected 
into the rat during the pressor assay• The thloglycolate had 
no effect on the blood pressure. 
Tacle c5. Effect of concentration and on thloglycolate 
inactivation of vasopressin 
AO le s thloglycolate 






Sol • B i'.'ohe 155 
Sol. 13 300 6.5 3 1/i ~ 185 
Sol. 14 .500 6.5 6 138 
Sol. 15a 500 8.0 ic4 155 
15 b 9c 9.5 
Table 26 shows that there v. 




if the près 
in the 
sor activ-
ity was not destroyed by thloglycolate. 
An alkaline solution and a high molar excess of thlo­
glycolate apparently were necessary for inactivation of syn­
thetic lysine vasopressin. With 600 moles of thloglycolate 
per mole of Sandoz, vasopressin and a pH of 8 both pressor and 
CRF activities were destroyed. The data from these inactiva-
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Plasma - cpd. E 
^Ug./lOO- ml 
Control Sample incr. 
s
-l\ um L.e r of r r t s . 
o-




Sol. 13 4 5 (S) ?. c±0.5 (7) 15.6+1.4 21 100 
Sol. 14 34.5 (S) 7.L+0.6 (6) 11.0+1.1 54 S3 
Sol. 15 39 (?) &.3+0.6 (5) IG.c+k.O 95 . 91 
tions ere shown in Taule £?. The reduction by thioglycol?te 
of tne disulfide bond of vasopressin abolishes both pressor 
end CRF activities. 
Pepsin inactivation studies 
In 1958 Royce and Sayers (lcC) stated that the cortico-
tropin-releasing activity of material they had isolated from 
the hypothalamus was destroyed by pepsin. The presser activ­
ity, however, was retained. In order to determine if this 
interesting separation of activities could be shown with syn­
thetic vasopressin, pepsin ws incubated with synthetic lysine 
vasopressin in several experiments. The ratio of pepsin to 
mllliunits of pressor activity (4yxg./cc. to 160 mU .-/cc • ) was 
approximately that used by Royce end Sayers. 
Table k.7 • Effect of 600 moles excess thioglycolFte on pressor and CRF activity 
















So1 • 56-S 75 0 
2l 3 (7) lx.7 + 0.4°- (8) 17.2 + -C..0 53 23 
Sol. 34-V 51 0 
3 %4 (6) 10.3 +"'1.7 (10) 10.0 + 0.9 0 0 
aKumuer of r;ts. 
CS LandFrd error of the mean 
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The vasopressin solutions were incucrted wi-th pepsin et 
37° C. for £ hours. Then the pH v;as changed to 7, end the 
solution was frozen until assayed. The CRF assays were- per­
formed first 'and then the pressor assays to determine "if there 
had c e'en any loos of pressor activity in sterne or during the 
CRF bioassays. In ïacle cB V represents du Vigneaud vaso­
pressin and S Sandoz. 





mU./do s e 
Plasma - cpd. 
M-9 . /100 ml. 




Sol. 3bV 41 (6)^6.c±C.7^ ( io)  17.3+1.k ' 110 95 
Sol. 49S 47 (8) 9.0+1.3 (7) &0.3+1.4 126 98 » 
aKumcer of rats. 
^Standard error of the mean. 
There was no loss of pressor activity after incubation 
with pepsin l'or two hours at 37° C. and also no destruction 
of CRF activity. Perhaps the pepsin-labile ACTH-releasing 
factor of Royce and Sayers was ©(,-CRF. This factor appears 
to be structurally related to IS'-: and therefore would prob­
ably ce degraded by pepsin. 
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SUMMARY 
Porcine posterior pituitary preparations were submitted to 
continuous electrophoresis, and the CE fractions were 
assayed for MSH, ACTH, pressor and CRF activities. 
The CRF and pressor activities were not separated by 
continuous electrophoresis; the CE fraction with the 
highest pressor activity showed the greatest ACTH-
releaslng activity. 
Cortlcotropin-releasing activity was measured in the 
Guillemln in vivo assay using nembutal-morphine blocked 
rats and fluorometrlc determination of plasma corticoids 
as the index of ACTH-release. 
All electrophoresis fractions, if assayed at a constant 
pressor dosage of.30 mU., gave increases in plasma level 
of corticosterone which were relatively constant within 
the range of the CRF assay. 
du Vigneaud synthetic lysine vasopressin was assayed for 
ACTH-releaslng activity; a linear response versus log-
dose relationship was established between 16.8 and 67 mU. 
of vasopressin. 
du Vigneaud vasopressin (262 U./mg.) was active in re­
leasing ACTH at 0.06yug, and is, therefore, more active 
than the purest preparations of of-CRF and (3 -CRF re­
ported in the literature. 
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7. Sariaoz synthetic lysine vasopressin rise [ > - r v e  a linear 
log-dose CRF' response curve between pressor dosages of 
. ^ 2 mU . to 70 mU. 
8. Injection of 67 ml*, of du Vip-neaud synthetic vasopressin 
into 'hypophysectoaiized rats gave-no increase in plasma 
corticoids indicating that the effect of vasopressin in 
the in vivo CRF assay was ? true corticotropin-releasing 
effect and not a direct action on the adrenals. 
9. The CRF nativity of the continuous electrophoresis frac­
tions was accounted for by the inherent ACTH-releasing' 
activity of the vasopressin pres. nt; no evidence for a 
@ - CRF was' found. 
10. Solutions of synthetic lysine vasopressin showed no loss 
of CRF or pressor activity for 4£ hours at -15° C., 
25° C. or -37° C. ; after 5-7 weens of storage in a deep 
freeze 45-72/-- of ucth activities were recovered. 
11. At 100° C., synthetic lysine vasopressin was n.ore stable 
to hydrolysis at pH 1.2 than at pH 11.5; both pressor 
and corticotropin-releas.ing activities were destroyed 
to the S8ii»e extent during hydrolysis. 
12• Reduction of tne disulfide ring of vasopressin at pH 8 
by 600 molar excess thioglycolate abolished both CRF 
and pressor activities. 
1-3. Pepsin did not destroy the pressor or the corticotropin-
releasing activity of synthetic lysine vasopressin. 
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